AP395A - Amine derivatives of oxo- and hydroxy-substituted hydrocarbons. - Google Patents

Amine derivatives of oxo- and hydroxy-substituted hydrocarbons. Download PDF

Info

Publication number
AP395A
AP395A APAP/P/1993/000504A AP9300504A AP395A AP 395 A AP395 A AP 395A AP 9300504 A AP9300504 A AP 9300504A AP 395 A AP395 A AP 395A
Authority
AP
ARIPO
Prior art keywords
amino
hydroxy
butyl
phenylbutyl
carbazate
Prior art date
Application number
APAP/P/1993/000504A
Other versions
AP9300504A0 (en
Inventor
Damian Wojciech Grobelny
Original Assignee
Narhex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU94040859/04A priority Critical patent/RU2126794C1/en
Priority to BR9306058A priority patent/BR9306058A/en
Priority to CA002130754A priority patent/CA2130754C/en
Priority to PCT/AU1993/000103 priority patent/WO1993018006A1/en
Priority to NZ249789A priority patent/NZ249789A/en
Priority to AU37391/93A priority patent/AU681342B2/en
Priority to EP93906370A priority patent/EP0633881B1/en
Priority to JP5515189A priority patent/JPH07504654A/en
Priority claimed from AU37391/93A external-priority patent/AU681342B2/en
Priority to US08/295,855 priority patent/US5679688A/en
Priority claimed from PCT/AU1993/000103 external-priority patent/WO1993018006A1/en
Priority to APAP/P/1993/000504A priority patent/AP395A/en
Application filed by Narhex Ltd filed Critical Narhex Ltd
Publication of AP9300504A0 publication Critical patent/AP9300504A0/en
Priority to CN93119079A priority patent/CN1090612C/en
Priority to US08/612,894 priority patent/US5888992A/en
Application granted granted Critical
Publication of AP395A publication Critical patent/AP395A/en
Priority to US08/900,733 priority patent/US5942504A/en
Priority to US09/255,551 priority patent/US6071895A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

The invention provides a new class of hydrazine derivatives of the general formula

Description

AMINE DERIVATIVES OF OXO- AND HYDROXY- SUBSTITUTED
HYDROCARBONS
TECHNICAL FIELD 5
The invention relates to certain amine derivatives and their use in the inhibition of human immunodeficiency virus (HIV, proteases and thus in the treatment of HIV viral infections such as acquired immunodeficiency syndrome (AIDS).
BACKGROUND ART
Human immunodeficiency virus (HIV) is a pathogenic retrovirus causing AIDS and its related disorders. The development of antiviral chemotherapy against AIDS has been the subject of an intense research 15 effort since the discovery of HIV. (For a recent review on molecular targets for AIDS therapy see Mitsua et al, Science, 1990, pp 1533-1544). The HIV Proteases (HIV PR), and aspartyl proteases, were first suggested as a potential target for AIDS therapy by Kramer et al. (Science. 231, 1580, 1986). Since that time the potential usefulness of HIV PR inhibitors as 20 effective agents in treatment of AIDS has been widely recognized (for a - review of the HIV PR as a therapeutic target see Tomaselli et al. Chimica pqqi. May 1991, pp 6-27 and Huff J.R., J.Med.Chem., 1991, 34, 2314- o **2327). Of the classical transition state mimics for aspartyl proteases, the hydroxyethylene, dihydroxyethylene, hydroxyethylamine and phosphinic acid 25 isosteres appear to provide the greatest affinity for HIV PR. Many inhibitors of HIV PR have been shown to have an antiviral activity at concentrations in ' the nanomolar range in the different cell systems and are described as such in the patent literature.
SUMMARY OF THE INVENTION
The invention provides a new class of compounds which are useful as inhibitors of retroviral proteases, particularly aspartyl proteases and more particularly HIV proteases, and which are effective in treating conditions characterized by unwanted activity of these enzymes, in particular acquired immune deficiency syndrome.
A first embodiment of the invention is directed to compounds of the general formula (I):
BAD ORIGINAL &
N*
R'z 0>
or pharmaceutically acceptable salts thereof, wherein:
R1 is a group R, wherein R is selected from the group consisting of hydrogen,
-R’H, -R’C(O)OR, -R'C(O)NH2, -R’C(O)NHR·’, -R’CtOWR’··,
-R'NHC(O)R, -R'NR,,,C(O)R” or -R'CIOJR, where R and R' are independently optionally substituted (C-,-C-j gjalkyl, typically (Ci-C^a'kY1; (C3-Ci8>cycloalkyl, typically (C3-C12)cycloalkyl;
(C3-C18)cycloalkyl(Ci-C-jelalkyl, typically {C3-C12)cycloalkyl(CvCg)alkyl; (Cg-C24>aryl, typically (Cg-C-j gjaryl; (C7-C25)aralkyl, typically {C7-C1 g)aratkyl; {C2-C1 g)alkenyl, typically (C2-C12)alkenyl;
<c8'c26iaralkenyl, typically (Cg-C-j glaralkenyl; (C2-Ci glalkynyl, typically (C2-Ci 2)θΙΙ<ΥπΥ|) (Cg-C26)aralkYnyl, typically (Cg-Cig)aralkynyl; or heterocyclic, and where R' is an optionally substituted divalent radical derived from (C-|-C-| glalkyl, typically (Ci-C-j2)alkyl; is (C3-C1glcycloalkyl, typically {C3-C12)cycloalkyl; (C3-C18)cycloalkyl{C-|-Ci 8)alkyl, typically (C3-C] 2)cycloalkyl(Ci-Cgjalkyl; (Cg-C24)aryl, typically (Cg-C-j gjaryl; (C7-C25)aralkyl, typically (C7-C1 gjaralkyl; (C2-C1 gjalkenyl, typically (C2-C12)alkenyl;
(Cg-C26)aralkenyl, typically (Cg-C-j glaralkenyl; (C2-C1 gjalkynyl, typically (C2-C-, 2)alkynyl; (Cg-C2g)aralkynyl, typically (Cg-Cig)aralkynyl; or heterocyclic, or R^ is
R4 < > -C—R5 \ ι
R6 where R4, R^ and R® are independently a group R as defined above, or R4 has the meaning of R as defined above and r5 and R^ taken together are =0, = S, =NHor = NR;
and R^ is
R D
I II
-N-B—C-Y where R is as previously defined; D is O or S; Y is hydrogen, -R or
-OR, where R is as previously defined, or is an amino acid, aza-amino acid or peptide residue in which any functional group present is optionally protected; and B is optionally absent or is (C-j-Cg)AP 0 0 0 3 9 5
BAD ORIGINAL O, alkylidene, wherein any one or more -CH2- groups may be replaced by -NR-, -NH-, -0- or -S- provided that the compound of Formula (I) does not contain a chain of three or more atoms which are not carbon, and wherein any H atom may be substituted by a group R as previously defined; and optionally Ν*, N, R1 and R taken together form a cyclic diazaalkane of the formula:
^-(CHR)p ^-N-N/ \
where p is 1 to 3, each R is independently as defined above and R3 is R, -NH2, -NHR, -NR2, -COOH, -COOL, -CHO, -C(O)R, -CN, halo, -CF3, -OL, -SR, -S(O)R, -S(O)2R, -CONH2, -CONHR, -CONR2, -NHOH, -NHOL, -NO2, =0, =S or -NHNH2, wherein each R is independently as defined above and each L is independently R or a hydroxyl protecting group which is labile in vivo;
or R2, N‘ and R4 together form a saturated or unsaturated cyclic, bicyclic or fused ring system as defined hereinafter which may be additionally substituted by -C(0)Y, where Y is as previously defined and R3 is X- W - A' - Q - A -, wherein:
A' and A independently are absent or (C-|-Cg)alkylidene, typically (C-|-C4)alkylidene which may be substituted with one or more substituents R as previously defined;
Q is —-CR— —C-CFL·— -CR-CRyi , it or i *
OL 0 OL
AP 0 0 0 3 9 5 where L and each R, independently of the others, are as previously defined, and optionally Q and A together, or Q and A’ together, or A’, Q and A together form part of a saturated or unsaturated cyclic, bicyclic or fused ring system as defined hereinafter;
W is absent or is N(R), 0 or S, wherein R is as previously defined; and X is hydrogen, or X1, where X1 is Ra- or RbC(O)- or RbS(O)z-, where z is 1 or 2 and Ra and Rb are independently (Ci-Cis)alkyl,
BAD ORIGINAL 0 typically (C-j-C^alkyl; (Cg-CjgJcycloalkyl, typically (C3-C-^cycloalkyl; (C3-C1 g)cycloalkyl(C-)-C-] g)alkyl, typically (C3-C12)cycloalkyl(C1 -Cg)alkyl; heterocyclic; (C-|-Cig)alkylheterocyclic, typically (C-j-C-j 2)alkylheterocyclic; heterocyclic(Cg-C24)aryloxy, typically heterocyclic(Cg-Cig)aryloxy; (C1-C1 g)alkoxy, typically (C-i-C^)alkoxy; (C-j -C-j g)alkoxy(C-| -C-j g)alkyl, typically (C-|-C-| 2>alkoxy(Ci-Ci2)alkyl; |C6-C245arYloxY(c1-c18>a,ky|- typically (Cg-C-|g)aryloxy(C-|-C-j 2)a,kyl; (Cg-C24)aryloxy{Ci-C-| gjalkoxy, typically (Cg-C-j g)aryloxy(Ci-Ci ylalkoxy; (Cg-C24)aryl, typically (Cg-C-| gjaryl;
{Cg-C24)aryl(C-j-C-| glalkyl, typically (Cg-C16)aryl(C-| -C-j 2)alkyl;
(Cg-C24)aryl(C-|-C-|g)alkylheterocyclic, typically (Cg-C16)aryl(C-|-Cl 2)aIkylheterocyclic; heterocyclicoxy(C-|-Ci g)alkyl, typically heterocyclicoxy(C-|-C-| 2)alkyl; (C-]-C-j gjalkylamino, typically f (CVCi 2)aIkylamino; di(C 1 -C-|gjalkylamino, typically di(C-|-C-] 2)15 alkylamino; (Cg-C24)arylamino, typically (Cg-C-| gjarylamino; di(C6-C24)arY|amino- typically di(Cg-Ci gjarylamino; (C7-C25)aralkylamino, typically (C7-C12)aralkylamino or di(C7-C25)aralkylamino, typically ditCy-C-j 2)aralkylamino; any of which may be optionally substituted as hereinbelow defined or substituted with a group Re, where Re is a group of the formula:
Rf 0
I II
Z-NH—CH-C— where Z has the meaning of Ra or Rb or is an acylated amino acid, C azaamino acid or peptide residue, and Rf is the side-chain of a natural amino acid in which any functional group present is optionally protected;
or X is Re as previously defined, or X is an optionally protected amino acid, azaamino acid or peptide residue; or when W is N(R), then X, N and the substituent R on N together may form a saturated or unsaturated cyclic, bicyclic or fused ring system as defined hereinbelow or N, A’ and the substituent R on N together form a saturated or unsaturated cyclic, bicyclic or fused ring system as defined hereinbelow.
Also included within the scope of the invention are compounds wherein two R substituents, not necessarily vicinal, taken together are optionally substituted {C2-C1 gjalkylidene, typically {C2-Cg)alkylidene.
Also included within the scope of the invention are compounds
BAD ORIGINAL wherein the Z-NH bond shown is replaced by a modified isosteric bond, such as CH3-NRa-, RaCH2-NRa-, CH3-CHRa-, HCH = CRa-, RaCH = CRa-, HCOCHRa-, RaCOCHRa-, HCHOHCHRa-, RaCHOHCHRa-, HNRaCO-, HCF = CRa-, RaCF = CRa-, RaS(O)-, RaS(O)2-, RaP(O)ORa-, RaP(O)(ORa)CH2-,
RaP(O)(ORa)O-, RaP(O)(ORa)S-, wherein each Ra is independently as previously defined.
As used herein, the term optionally substituted means that one or more hydrogen atoms may be replaced by a group or groups selected from: -F, -Cl, -Br, -I, -CF3, -OH, -ORIV, -NH2, -NHRIV, -NRIVRV, -CN, -NO2, -SH,
-SRIV, -SORIV, -SO2RIV, =0, =S, =N0H, = NORIV, -NH0H, -NHORIV, -CHO, where R,v and Rv are independently (C-j-Cis)alkyl, typically <C-|-C-| 2)alkyl; (C3-Cig)cycloalkyl, typically (C3-C-| 2)cycloalkyl; (C3-Cig)cycloalkyl(C-j-C1 gjalkyl, typically (C3-C]2)cYdoalkyl(Ci-Cg)alkyl; (Cg-C24)aryl, typically (Cg-C-j g)aryl; (C7-C25)aralkyl, typically (C7-Ci g)aralkyl;
(C2-C-iQ)alkenylz typically (C2-Ci 2)alkenyl; (Cg-C2g)aralkenyl, typically (Cg-C-j g)aralkenyl; (C2-C-| glalkynyl, typically (C2-C-| 2)alkynyl; (Cg-C2g)aralkynyl, typically (Cg-C-j gjaralkynyl; or heterocyclic.
As used herein, the term alkyl includes within its meaning straight and branched chain alkyl groups. Examples of such groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, amyl, isoamyl, sec— amyl, 1,2-dimethylpropyl, 1,1-dimethyl-propyl, hexyl, 4-methylpentyl, 1methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 2,2dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 1,2,2trimethylpropyl, 1,1,2-trimethylpropyl, heptyl, 5-methylhexyl, 1-methylhexyl,
2,2-dimethylpentyl, 3,3-dimethylpentyl, 4,4-dimethylpentyl, 1,2dimethylpentyl, 1,3-dimethylpentyl, 1,4-dimethyl-pentyl, 1,2,3-trimethylbutyl,
1,1,2-trimethyIbutyl, 1,1,3-trimethylbutyl, octyl, 6-methyIheptyl, 1methylheptyi, 1,1,3,3-tetramethylbutyl, nonyl, 1-, 2-, 3-, 4-, 5-, 6- or 7methyl-octyl, 1-, 2-, 3-, 4- or 5-ethylheptyl, 1-, 2- or 3-propylhexyl, decyl, 1-,
2-, 3-, 4-, 5-, 6-, 7- or 8-methylnonyl, 1-, 2-, 3-, 4-, 5- or 6-ethyloctyI, 1-, 2-,
3- or 4-propylheptyl, undecyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-methyldecyl, 1, 2-, 3-, 4-, 5, 6- or 7-ethylnonyl, 1-, 2-, 3-, 4- or 5-propyloctyl, 1-, 2- or 3butylheptyl, 1-pentylhexyl, dodecyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- or 10methylundecyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-ethyIdecyl, 1-, 2-, 3-, 4-, 5- or 635 propylnonyl, 1-, 2-, 3- or 4-butyloctyl, 1- or 2-pentylheptyl, and the like.
A used herein, the term cycloalkyl refers to mono- or polycyclic alkyl groups, or alkyl substituted cyclic alkyl groups. Examples of such groups include cyclopropyl, methylcyclopropyl, cyclobutyl, methylcyclobutyl,
AP 0 0 0 3 9 5
BAD ORIGINAL £ cyclopentyl, methylcyclopentyl, ethylcyclopentyl, cyclohexyl, methylcyclohexyl, ethylcyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, decahydronaphthyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl and the like.
As used herein, the term cycloalkylalkyl refers to an alkyl group substituted with a cycloalkyl group as defined above.
As used herein, the term alkenyl includes within its meaning ethylenically mono-, di- or poly-unsaturated alkyl or cycloalkyl groups as previously defined. Examples of such alkenyl groups are vinyl, allyl, 110 methylvinyl, butenyl, iso-butenyl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl,
1-heptenyl, 3-heptenyl, 1-octenyl, cyclooctenyl, 1-nonenyl, 2-nonenyl, 3nonenyl, 1-decenyl, 3-decenyl, 1,3-butadienyl, 1,4-pentadienyl, 1,3cyclopentadienyl, 1,3-headienyl, 1,4-hexadienyl, 1,3-cyclohexadienyl, 1,415 cyclohexadienyl, 1,3 cycloheptadienyl, 1,3,5-cycloheptatrienyl and 1,3,5,7cyclooctatetraenyl.
As used herein, the term alkynyl” includes within its meaning acetylenically unsaturated alkyl groups as previously defined. Examples of such alkynyl groups are ethynyl, propynyl, n-butynyl, n-pentynyl, 3-methyl-120 butynyl, n-hexynyl, methyl-pentynyl, (C7-C12)alkynyl and (C7.C12)cycloalkynyl.
As used herein, the term alkylidene refers to optionally unsaturated divalent alkyl radicals. Examples of such radicals are -CH2-, -CH2CH2-, -CH = CH-, -CH2CH2CH2-, -C{ = CH2)CH2-, -CH2CH = CH-, -{CH2)4-,
-CH2CH2CH =CH-,-CH2CH = CHCH2-, and-(CH2)f-where r is 5-8. The term also refers to such radicals in which one or more of the bonds of the radical from part of a cyclic system. Examples of such radicals are groups of the structure
96L000
BAD ORIGINAL ft
S 6 £ 0 0 0 dV and similar groups wherein any N or 0 atom is replaced by S.
As used herein, the term aryl refers to single, polynuclear, conjugated and fused residues of aromatic hydrocarbons or aromatic heterocyclic ring systems. Examples of such groups are phenyl, biphenyl, terphenyl, quaterphenyl, naphthyl, tetrahydronaphthyl, anthracenyl, dihydroanthracenyl, benzanthracenyl, dibenzanthracenyl, phenanthrenyl, fluorenyl, pyrenyl, indenyl, azulenyl, chrysenyl, pyridyl, 4-phenylpyridyl, 3-phenylpyridyl, thienyl, furyl, pyrryl, indolyl, pyridazinyl, pyrazolyl, pyrazinyl, thiazolyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothienyl, purinyl, quinazolinyl, phenazinyl, acridinyl, benzoxazolyl, benzothiazolyl and the like. In all cases, any available position of the fused or conjugated bicyclic system can be used for attachment to the remainder of the molecule of formula (I,.
BAD ORIGINAL &
ίο
As used herein, the term aralkyl refers to alkyl groups substituted with one or more aryl groups as previously defined. Examples of such groups are benzyl, 2-phenylethyl and 1-phenylethyl.
As used herein, the terms aralkenyl and aralkynyl refer to alkenyl and alkynyl groups respectively, substituted with one or more aryl groups as previously defined. Examples of such groups are styryl, phenylacetylenyl and
2-phenyl-2-butenyl.
As used herein the term saturated or unsaturated cyclic, bicyclic or fused ring system refers to a cyclic system of up to 16 carbon atoms, up to 3 of which may be replaced by 0, S or N, which ring system may be substituted with one or more of R, -NH2, -NHR, -NR2, -COOH, -COOL, -CHO, -C(0)R, -CN, halo, -CF3, -OL, -SR, -S(O)R, -S(O)2R, -C0NH2, -CONHR, -CONR2, -NHOH, -NHOL, -NO2, =0, =S or -NHNH2; wherein each L and R are independently as previously defined. Examples of such ring systems are
As used herein, the term heterocyclic refers to any 3- to 16-membered monocyclic, bicyclic or polycyclic ring containing, for 3- and 4membered rings, one heteroatom; for 5-membered rings, one or two heteroatoms; for 6- and 7-membered rings, one to three heteroatoms; for 8and 9-membered rings, from one to four heteroatoms; for 10- and 11-membered rings, from one to five heteroatoms; for 12- and 13-membered rings, from one to six heteroatoms; for 14- and 15-membered rings, from one to seven heteroatoms; and for 16-membered rings, from one to eight heteroatoms; the heteroatom(s) being independently selected from oxygen, nitrogen and sulphur. The term heterocyclic includes any group in which a heterocyclic ring is fused to a benzene ring. Examples of heterocyclics are pyrryl, pyrimidinyl, quinolinyl, isoquinolinyl, indolyl, piperidinyl, pyridinyl,
BAD ORIGINAL ft furyl, thiophenyl, tetrahydrofuryl, imidazolyl, oxazolyl, thiazolyl, pyrenyl, oxazolidinyl, isoxazolyl, isothiazolyl, isoxazolidinyl, imidazolidinyl, morpholinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, furfuryl, thienyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzothiadiazolyl, tetrazolyl, triazolyl, thiadiazolyl, benzimidazolyl, pyrrolinyl, quinuclidinyl, azanorbornyl, isoquinuclidinyl and the like. Nitrogen-containing heterocyclics may be substituted at nitrogen with an oxygen atom. Sulfurcontaining heterocyclics may be substituted at sulfur with one or two oxygen atoms.
Configurations which result in unstable heterocyclics are not included within the scope of the definition of heterocyclic or saturated or unsaturated cyclic, bicyclic or fused ring system.
As used herein, the term alkylheterocyclic refers to a heterocyclic group as defined above, which is substituted with an alkyl group as defined above.
As used herein, the term heterocyclic-oxy-alkyl refers to a group of the formula heterocyclic-O-alkyl, wherein the heterocyclic and alkyl are as defined above.
As used herein, the term alkoxy refers to a group of the formula 20 alkyl-Ο-, wherein the alkyl group is as defined above.
As used herein, the term aryloxy refers to a group of the formula aryl-Ο-, wherein the aryl group is as defined above.
As used herein, the term alkanoyloxy refers to a group of the formula alkyl-C(O)O-, wherein the alkyl group is as defined above.
As used herein, the term amino acid refers to a synthetic or naturally occurring compound of the formula H2NCH(R)COOH, wherein R is as defined above.
As used herein, the term azaamino acid refers to an amino acid in which the CH(R) group has been replaced by a group -N(R)-, wherein R is as defined above.
Suitable pharmaceutically acceptable salts of the compound of formula (I) are salts of pharmaceutically acceptable inorganic acids such as hydrochloric, sulphuric, phosphoric, nitric, carbonic, boric, sulfamic, hydrobromic or hydriodic, or with pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, maleic, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, toluenesulphonic, benzenesulphonic, salicylic, sulphanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic,
BAD ORIGINAL ft ascorbic or valeric.
The expression protected as used herein is intended to mean that a reactive group such as hydroxyl or amino is substituted by replacing a hydrogen atom of the reactive group in order to protect such groups during synthesis and/or to prevent premature metabolism of the compound of formula (I) after administration to a patient before the compound can reach the desired site of action. Suitable protecting groups for hydroxyl substituents include substituted methyl ethers, for example, methoxymethyl, benzyloxymethyl and the like, vinyl, acyl and carbonate groups. Suitable protecting groups for amino substituents include acyl groups such as acetyl, t-butylacetyl, t-butyloxycarbonyl, benzoyl or carbobenzyloxycarbonyl, benzyloxycarbonyl, pyridinemethoxycarbonyl, quinoline-2-carbonyl or an aminoacyl residue. Protecting groups which are included in the compound of formula (I) must be amenable to hydrolytic or metabolic cleavage in vivo.
Usually, the compound of the general formula (I) will have the structure represented by formula (IA):
where X, Q, V and each R is independently as previously defined, a and b are independently 0 to 4 and c is 0 to 6, or where two R groups, not necessarily vicinal, taken together are -(CHR18)mwhere m is 2-8 and R18 has the meaning of R.
More usually, the compound of the general formula (I) will have the structure represented by formula (IB):
R19 0
I I!
XNX ,QX XNX ZCX X A' A Ν Y
I
R20 (IB) where X, R, A', Q, A and Y are as previously defined or either or both of A and A' are absent, and R19 and R^O have the meaning of R or where R19, Ν*, N and R2® together form a cyclic diazaalkane as previously defined.
Most usually, the compound of the general formula (I) will have the structure represented by formula (IC, or (ID,:
BAD ORIGINAL £
X io
C' wherein:
C'
R21 R22 R24
R OH R23 0 R21 R22 R24
I I ι
X
I II
R 0
Il ι II
R23 0
R is as defined above;
R21 is hydrogen, optionally substituted (C-j-C-]2)alkyl; optionally substituted (Cg-C-|2)3ryl; optionally substituted {C7-C1 gjaralkyl;
R22 is hydrogen, (C-j-Cglalkyl; (C7-C1 glaralkyl, or when r21 ancj r22 taken together are -(CH2)n-. wherein n is 2 to 8;
r23 is hydrogen; optionally substituted (C-j-C^la^yl; (Cg-C-ι 2)aryl; (C7-C-J g)aralkyl; or wherein r22 and r23 taken together are -(CHR25jm.( wherein m is 3-6 and r25 has the meaning of R1(3;
R24 is hydrogen; optionally substituted (C-,-Ci2)311^ optionally substituted (C7-C1 g)aralkyl; or optionally substituted (Cg-C-j 2)aryl;
or wherein NR23 and NR24 taken together may be a cyclic diazaalkane as previously defined; and
X and Y are as previously defined.
Representative compounds in accordance with the invention are:
(i) t-butyl 3-isopropyl-3-I(2R or S,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]carbazate, (ii) t-butyl 3-isopropyl-3-{(2R or S,3S)-2-hydroxy-3-(N-quinaldoyl-Lvalyl)amino-4-phenylbutyl]carbazate, (iii) t-butyl 3-isopropyl-3-((2R or S,3S)-2-hydroxy-3-(N-quinaIdoyl-Lasparaginyl)amino-4-phenylbutyl]carbazate, (iv) t-butyl 3-isopropyl-3-[(3S)-2-oxo-3-(N-quinaldoyl-Lasparaginyl)amino-4-phenylbutyl]carbazate/ (v) t-butyl 3-(1-methyl-3-phenylpropen-3-yl)-3-[(2R or S,3S)-2-hydroxy3-(phenylmethoxycarbonyl)amino-4-phenylbuty!]carbazate, (vi) t-butyl 3-(l-methyl-3-phenylpropyl)-3-[(2R or S,3S)-2-hydroxy-3-(Nquinaldoyl-L-asparaginyl)amino-4-phenylbutyl]carbazate, (vii) cis-1,6-3-t-butoxycarbonyl-4-l(2R or S,3S)-2-hydroxy-3-amino-4phenylbutyl]-3,4-diazabicyclo[4.4.0]decane,
BAD ORIGINAL (viii, cis-1,6-3-t-butoxycarbonyl-4-I(2R or S,3S)-2-hydroxy-3(phenylmethoxycarbonyl)amino-4-phenylbutyl]-diazabicyclo[4.4.0]decane, (ix) cis-1,6-3-t-butoxycarbonyl-4-{(2R or S,3S)-2-hydroxy-3-(Nquinaldoyl-L-valyl)amino-4-phenylbutyl]-3,4-diazabicyclo(4.4.0]decane (x) cis-1,6-3-t-butoxycarbonyl-4-[(2R or S,3S)-2-hydroxy-3-[N-(2pyridyl)methoxycarbonyl)-L-valyl)amino-4-phenylbutyl]-3,4-diazabicyclo[4.4.0Jdecane (xi) cis-1,6-3-t-butoxycarbonyl-4-((2R or S,3S)-2-hydroxy-3-(Nquinaldoyl-L-asparaginyl)amino-4-phenylbutyl]-3,4-diazabicyclo[4.4.0]decane, io (xii, cis-1,6-3-t-butoxycarbonyl-4-[(2R or S,3S)-2-hydroxy-3-(Nquinaldoyl-L-glutaminyl)amino-4-phenylbutylJ-3,4-diazabicyclo[4.4.0jdecane, (xiii, cis-1,6-3-t-butoxycarbonyl-4-[(2R or S,3S)-2-hydroxy-3-(Nquinaldoyl-L-threonyl)amino-4-phenylbutyl]-3,4-diazabicyclo[4.4.0Jdecane, (xiv) 2-t-butoxycarbonyl-3-[(2R or S,3S)-2-hydroxy-3-(phenylmethoxy15 carbonyl)amino-4-phenylbutyl]-2,3-diazabicyclol2.2.1 Jhept-5-ene, (xv) 2-t-butoxycarbonyl-3-((2R or S,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]-2,3-diaza-bicyclo[2.2.1 jheptane, (xvi) 2-t-butoxycarbonyl-3-((2R or S,3S)-2-hydroxy-3-(N-(2-pyridyl)methoxy-L-valyl)amino-4-phenylbutylj-2,3-diaza-bicyclo(2,2.1 jheptane, (xvii) 2-iN-(1S)(2-methyl-1-methoxycarbonylpropyl)carbamoylj-3-((2R or • S,3S)-2-hydroxy-3-[N-(2-pyridyl)methoxy-L-valyljamino-4-phenylbutyl)-2,3diazabicyclo(2.2.1 jheptane, (xviii, 2-t-butoxycarbonyl-3-((2R or S,3S)-2-hydroxy-3-(N-quinaldoyl-Lasparaginyl)amino-4-phenylbutylj-2,3-diazabicyclo(2.2.1 jheptane, (ixx, 1-(2-(2-pyridyl)methoxycarbonylamino-]benzoyl-2-[(2R or S,3S)-2hydroxy-3-(N-quinaldoyl-L-asparaginyl)amino-4-phenylbutylj-2-isopropylhydrazine, (xx) 2-t-butoxycarbonyl-3-((2R or S,3S)-2-hydroxy-3-(N-quinaldoyl-Lasparaginyl)amino-4-phenylbutyl]-1,2,3,4-tetrahydrophthalazine, (xxi) 1-trimethylacetyl-2-[(2R or S,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phyenylbutyl]-2-isopropylhydrazine, (xxii) 1-trimethylacetyl-2-[(2R or S,3S)-2-hydroxy-3-(N-quinaldoyl-Lasparaginyl) amino-4-phenylbutyl]-2-isopropylhydrazine, (xxiii) 1-(t-butylamino)carbonyl-2-[(2R or S,3S)-2-hydroxy-3-(N-quinaldoyl35 L-asparaginyl)amino-4-phenylbutylj-2-isopropylhydrazine, (xxiv, t-butyl 3-isopropyl-3-((2R or S,3S)-2-hydroxy-3-(N-picolinoyl-Lasparaginyl)amino-4-phenylbutyl]carbazate, (xxv) t-butyl 3-isopropyl-3-[{2R or S,3S)-2-hydroxy-3-(N-(2-pyridyljS 6 £ 0 0 0 dV
BAD ORIGINAL ft methoxycarbonyl-anthraniloyl)amino-4-phenylbutyl]carbazate.
(xxvi) t-butyl 3-benzyl-3-((2R or S,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl)carbazate, (xxvii) t-butyl 3-benzyl-3-[(2R or S,3S)-2-hydroxy-3-(N-quinaldoyl-L5 asparaginyl)amino-4-phenylbutyl]carbazate, (xxviii) t-butyl 3-cyclohexyl-3-I(2R or S, 3S)-2-hydroxy-3-(phenyl-methoxycarbonyl)amino-4-phenylbutyl]carbazate, (xxix) t-butyl 3-cyclohexyl-3-[(2R or S,3S)-2-hydroxy-3-(N-quinaldoyl-Lasparaginyl)amino-4-phenylbutyl]carbazate, (xxx) t-butyl 3-isopropyl-3-[(2RorS,3S)-2-hydroxy-3-(N-{1-carbamoylmethyl)acryloyl)amino-4-phenylbutyl)carbazate, (xxxi) t-butyl 3-isopropyl-3-[(2R or S,3S)-2-hydroxy-3-(N-(2(RS)-3-tertbutylthio-2-carbamoyl-methylpropionyl)amino-4-phenylbutyl]carbazate, (xxxii) t-butyl 3-isopropyl-3-[(2R or S,3S)-2-hydroxy-3-(N-(1 -benzoyl-L15 asparaginyl)amino-4-phenylbutyl]carbazate, (xxxiii) 1-t-butyloxycarbonyl-2-[(2R or S,3S)-2-hydroxy-3-(phenylmethoxycarbonyI)amino-4-phenylbutyl]hexahydropyridazine, (xxxiv) 1-t-butyloxycarbonyl-2-l(2R or S,3S)-2-hydroxy-3-(N-quinaldoyl-Lasparaginyl)amino-4-phenylbutyl)hexahydropyridazine, (xxxv, cis-1,6-3-t-butoxycarbonyl-4-[(2R or S, 3S)-2-hydroxy-3-(Nquinaldoyl-3-cyano-L-alanyl)amino-4-phenylbutyl]-3,4-diazabicyclo[4,4,0]decane.
The structures of representative compounds of the invention are as follows:
O
Λ .But
CK2Ph H
But
bad ORIGINAL
S 6 £ 0 0 0 dV
The compound of formula (I), (IA), (IB), (IC) or (ID) can exist in optically isomeric forms and the present invention includes within its scope all these forms in all proportions including all diastereoisomers and racemic mixtures.
The compounds of formula (I) may be prepared by known methods for the synthesis of substituted amines. For example, a compound of the formula
R4 R D c 1 1 11 r5_C-n-N-B-C-Y I I R6 R2 may be prepared by reaction of an amine of the formula
BAD ORIGINAL
Compounds of formula (IA) may be prepared by reacting an amine of
R D
I II
HN-N-B-C-Y ι
R2 with a substituted alkyl halide of the formula R4
R5—C—Hal ι
R6 formula with a halide of formula
Compounds of formula (IB) may be prepared by reacting an amine of
formula R19 0 1 II Hx XN > 1 R20
with a halide of formula R |
1 XQX Hal X A’ A
The compounds of formula (IC) can be prepared by reacting
compound of formula (II) R21
X -N-C-C-C-R22 1 1 I (ll)
J 1 1 R Η H
λρ n non i wherein X, R2\ R22 and R have the significance given earlier, with a compound of formula (III)
BAD ORIGINAL
R23 Ο
H-N-N-C-Y (III)
R24 wherein r23# r24 ancj γ have the significance given earlier.
A compound of formula (ID) may be obtained from a compound of formula (IC) by oxidation in accordance with known methods of oxidative transformations of alcohols to ketones.
A compound of formula (ID) may be also be obtained by reacting a compound of formula (Ila)
(Ha) wherein X, R, R21 and R22 are as previously defined and Hal is a group 10 selected from -Cl, -Br, -I or -OS(O)2R« with a compound of formula (III).
The methods of preparation of compounds of formula (IC) and (ID) may be represented by the following general Schemes I to 3. In the Schemes presented herein, the following abbreviations are made:
AA refers to amino acid or amino acid residue; AcCN refers to aceto15 nitrile; BOP refers to benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate; CBZ refers to carbobenzoxy; CDI refers to N,N'carbonyldiimidazole; DMF refers to dimethylformamide; DMSO refers to dimethylsulfoxide; HBT refers to 1-hydroxybenzotriazole; Py refers to pyridine; Py.xSOg refers to the pyridine complex of sulfur trioxide; RT refers to room temperature and L-Val refers to L-valine.
S 6 £ 0 0 0 dV
BAD ORIGINAL t7
SCHEME 1
R21 0
X-N-C-C-C—R22 +
I I I
R Η H
R23 0
I II
H-N-N-C-Y ι
R24
SCHEME 2
R2i R22
X-N-C-C-C-Hal I II
R 0
R» 0
I II
H-N-N-C-Y ι
R24
S 6 £ 0 0 0 dV
BAD ORIGINAL &
OH (i) CCH, dioxane (ii) LiOH, AAAvater (ii) acid
Z AA ,0H
SCHEME 3
R OH R23 0
N„ Λ
N Y
CBZ' .N
ι
R21 R22 R24
H2, Pd/c
R OH R23 O
I
R21 R22 R24
H'
-N
BOP, HBT,(iPr)2NEt/DMF
O R OH R23 O
Λ..Λ
A<n
Ν Y R21 R22 R24
DMSO, PyxSO3, Et3N
T
O R 0 R23 0 zA<W,Ay
R21 R22 R24
The reaction schemes illustrated can be carried out by generally 5 known methods as exemplified hereinafter. The amino acids or peptide mimics for use in the synthesis of compounds of this invention are generally commercially available or may be prepared by conventional methods of organic chemistry.
Synthetic routes to the intermediates (II), (Ila) and (III) are readily
BAD ORIGINAL ft available. The chiral aminoalkylepoxides of formula (II, can be obtained using methods described in the following:
(a, Evans, B.E., et al., J, Org. Chem.. 50. 4615-4625 (1985);
(b) Luly, J.R., et al., J. Org, Chem.. 52, 1487-1492 (1987);
(c) Handa, B.K., et al., European Patent Application No. 346,847-A2 (1989) and (d) Marshall, G.R., et al., International Patent Application No W091/08221.
The N-protected aminoalkyl halomethylketones (Ila) are commercially io available or can be prepared using methods described in:
(e) Rich, et al., J. Med. Chem.. 33, 1285-1288 (1990) and (f, Reference (cf) above.
The hydrazide intermediates (III) can be obtained using known methods such as those described in the following:
(g, Dutta, A.S., et al., J. Chem. Soc. Perkin Trans. I. (1975, 17121720, (h, Ghali, N.I., et al., J, Org. Chem.. 46, 5413-5414 (1981), (i) Gante, J., Synthesis (1989, 405-413 and (j) Houben-Weyl's Methoden der Organische Chemie, vol. 16a, Part 1, pp 421-855; Georg Thieme Verlag, Stuttgart (1990)
A second embodiment of the invention is directed to pharmaceutical compositions comprising a compound of formula (I) together with one or more pharmaceutically acceptable carriers, diluents, adjuvants and/or excipients.
In a third embodiment of the invention there is provided a method for inhibiting retroviral proteases in a mammal in need of such inhibition, comprising administering to the mammal an effective amount of a compound of the first embodiment or of a composition of the second embodiment. In one form of the third embodiment, there is provided a method for the treatment or prophylaxis of HIV viral infections such as AIDS.
For inhibiting retroviral proteases or the treatment of HIV viral infections, a composition of the second embodiment may be administered orally, topically, parenterally, e.g. by injection and by intra-arterial infusion, rectally or by inhalation spray.
For oral administration, the pharmaceutical composition may be in the form of tablets, lozenges, pills, troches, capsules, elixirs, powders, granules, suspensions, emulsions, syrups and tinctures. Slow-release, or delayedrelease, forms may also be prepared, for example in the form of coated
S 6 £ 0 0 0 dV
BAD ORIGINAL particles, multi-layer tablets or microgranules.
Solid forms for oral administration may contain pharmaceutically acceptable binders, sweeteners, disintegrating agents, diluents, flavourings, coating agents, preservatives, lubricants and/or time delay agents. Suitable binders include gum acacia, gelatin, corn starch, gum tragacanth, sodium alginate, carboxymethylcellulose or polyethylene glycol. Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharine. Suitable disintegrating agents include corn starch, methylcellulose, polyvinylpyrrolidone, xanthan gum, bentonite, alginic acid or agar. Suitable io diluents include lactose, sorbitol, mannitol, dextrose, kaolin, cellulose, calcium carbonate, calcium silicate or dicalcium phosphate. Suitable flavouring agents include peppermint oil, oil of Wintergreen, cherry, orange or raspberry flavouring. Suitable coating agents include polymers or copolymers of acrylic acid and/or methacrylic acid and/or their esters, waxes, fatty alcohols, zein, shellac or gluten. Suitable preservatives include sodium benzoate, vitamin E, alpha-tocopherol, ascorbic acid, methyl paraben, propyl paraben or sodium bisulphite. Suitable lubricants include magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc. Suitable time delay agents include glyceryl monostearate or glyceryl distearate.
Liquid forms for oral administration may contain, in addition to the above agents, a liquid carrier. Suitable liquid carriers include water, oils such as olive oil, peanut oil, sesame oil, sunflower oil, safflower oil, arachis oil, coconut oil, liquid paraffin, ethylene glycol, propylene glycol, polyethylene glycol, ethanol, propanol, isopropanol, glycerol, fatty alcohols, triglycerides or mixtures thereof.
Suspensions for oral administration may further comprise dispersing agents and/or suspending agents. Suitable suspending agents include sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, sodium alginate or cetyl alcohol. Suitable dispersing agents include lecithin, polyoxyethylene esters of fatty acids such as stearic acid, polyoxyethylene sorbitol mono- or di-oleate, -stearate or -laurate, polyoxyethylene sorbitan mono- or di-oleate, -stearate or -laurate and the like.
The emulsions for oral administration may further comprise one or more emulsifying agents. Suitable emulsifying agents include dispersing agents as exemplified above or natural gums such as gum acacia or gum tragacanth.
For topical administration, the pharmaceutical composition may be in the form of a cream, ointment, gel, jelly, tincture, suspension or emulsion.
AP 0 0 0 3 9 5
BAD ORIGINAL
The pharmaceutical composition may contain pharmaceutically acceptable binders, diluents, disintegrating agents, preservatives, lubricants, dispersing agents, suspending agents and/or emulsifying agents as exemplified above.
For parenteral administration, the compound of formula I or its sal; 5 may be prepared in sterile aqueous or oleaginous solution or suspension.
Suitable mono-toxic parenterally acceptable diluents or solvents include water, Ringer's solution, isotonic salt solution, 1,3-butanediol, ethanol, propylene glycol or polyethylene glycols in mixtures with water. Aqueous solutions or suspensions may further comprise one or more buffering agents, io Suitable buffering agents include sodium acetate, sodium citrate, sodium borate or sodium tartrate, for example.
For rectal administration, the compound of formula I is suitably administered in the form of an enema or suppository. A suitable suppository may be prepared by mixing the active substance with a non-irritating excipient which is solid at ordinary temperatures but which will melt in the rectum. Suitable such materials are cocoa butter and polyethylene glycols. Suitable enemas may comprise agents as exemplified above with reference to forms for topical administration.
Suitably, an inhalation spray comprising a compound of formula I will be in the form of a solution, suspension or emulsion as exemplified above. The inhalation spray composition may further comprise an inha'able propellant of low toxicity. Suitable propellants include carbon dioxide or nitrous oxide.
The dosage form of the compound of formula I will comprise from 0.01% to 99% by weight of the active substance. Usually, dosage forms according to the invention will comprise from 0.1% to about 10% by weight C of the active substance.
The compound of formula I may be administered together or sequentially with 1 or more other active substances known or believed to be effective for the treatment of HIV viral infections. Examples of such other active substances include AZT and acyclovir.
BEST MODE OF CARRYING OUT THE INVENTION
Methods for the preparation of compounds of formula (IC, are described in the following Schemes 1a and 2a:
AP 0 0 0 3 9 5
BAD ORIGINAL $
SCHEME 1a
PhCH2 0 x-n-c-c-c-h
I I I
Η Η H
R27 0 + 1 11 + H-N-N-C-Y
I
R2B (i) iPrOH; 60-90’C;12 hr Yield 70-90%. or (ii) AJjO3; ether; RT; 12-24hr; Yield 30-45%
ZY
C
II
R27 0
SCHEME 2a
CH2Ph
X-N-C-C-CHrHal I II
H 0
R27 O
I II + H__N_N_C_Y I
R28 (i) Nal/DMF or AcCN; 1 hr; RT; (i) NaHCO3 or tertiary amine;
2-12 hr RT (»i)NaBH4;30 min; RT
/Ν /Y c
II
O
S 6 £ 0 0 0 dV
BAD ORIGINAL
Scheme 3a presents an alternative method of preparation of compounds of formula (IC) and (ID):
SCHEME 3a
(i) CDI, dioxane; RT; 30 min (ii) LiOH, L-Val in water (Si) pH=2; Yield 72%
T
CB2
N i
H
O
CH2Ph
H2, 10% Pd/C,methanol RT; Yield -100%
Pr' 0
L,A
N' ι
H
OBut
OBut
BOP, HBT, (Pd)2NEt in DMF RT, 12 Hrs; Yield 79% t
Compositions of the second embodiment may be prepared by means
BAD ORIGINAL known in the art for the preparation of pharmaceutical compositions including blending, grinding, homogenising, suspending, dissolving, emulsifying, dispersing and mixing of the compound of formula (I) together with the selected excipient(s), carrier(s), adjuvant(s) and/or diluent(s).
In the method for the treatment of HIV viral infections in accordance with the third embodiment of the invention, a compound of the first embodiment will usually be administered orally or by injection. A suitable treatment may consist of the administration of a single dose or multiple doses of the compound of formula (I) or of a composition of the second embodiment. Usually, the treatment will consist of administering from one to five doses daily of the compound of formula (I) for a period of from one day to several years, up to the lifetime of the patient. Most usually, the treatment will consist of the administration of the compound of formula (I) for a period of from one day to one year.
The administered dosage of the compound of formula I can vary and depends on several factors, such as the condition of the patient. Dosages will range from O.Olmg to 200 mg per kg. Usually, the dose of the active substance will be from O.Olmg to 10mg per kg of body weight.
Examples of dosage forms in accordance with the invention are as follows:
Tablet
Compound of formula I 0.01 to 20 mg, generally 0.1
10mg
Starch 10 to 20 mg
Lactose 100 to 250 mg
Gelatin 0 to 5 mg
Magnesium stearate 0 to 5 mg
CaDSule
Compound of formula I 0.01 to 20 mg, generally 0.1
10mg
Glycerol 100 to 200 mg
Distilled water 100 to 200 mg
Saccharin 0 to 2 mg
Methyl Paraben 1 to 2 mg
Polyvinylpyrrolidone 0 to 2 mg
bad original έ
Iniectable solution
Compound of formula I 0.01 to 20 mg, generally 0.1 to 10mg
Sodium chloride 8.5 mg
Potassium chloride 3 mg
Calcium chloride 4.8 mg
Water for injection, q.s. to 10 ml
Elixir
Compound of formula I 0.01 to 20 mg, generally 0.1 to 10mg
Sucrose 100 mg
Glycerol 2ml
Carboxymethylcellulose 20mg
Cherry flavour 2 mg
Water q.s. to 10 ml
EXAMPLES
Examples of compounds of formula (I, are those compounds of
formula (IV, presented in Table 1:
CH2Ph R^e
χ.. a /x y λ
N
I
H
OH R27 o ϋ 6 £ 0 0 0 dV
TABLE 1
No. Example X
No.
1. (8) CBZR27 r28 t-BuO2a. (10) QC-Asnt-BuO2b. (23) QC-Asnt-BuO2b.A. (23A, QC-Asnt-BuOBAD ORIGINAL
3. (9) QC-Valt-BuO4. (12) QC-GIn5. (13) QC-Thr6. (11) PC-Val26 t-BuOt-BuOt-BuO-
7A. (3) QC-Asn- i-Pr- H t-BuO-
7B. (20) QC-Asn- i-Pr- H t-BuC-
8. (4) QC-Asn- i-Pr- H (2-PCNH)Ph-
9. (2) QC-Val- i-Pr- H t-BuO-
10. (16) PC-Val- o t-BuO-
1 1. (18) QC-Asn- t-BuO-
©
AP 0 0 0 3 9 5
12. (7) QC-Asn- L Π 3 H t-BuO-
13. (25) QC-Asn- i-Pr- H t-Bu-
14. (26) QC-Asn- i-Pr- H t-BuNH-
15. (27) PIC-Asn- i-Pr- H t-BuO-
16. (30) QC-Asn- Bzl- H t-BuO-
17. (32) QC-Asn- cyclohexyl H t-BuO-
18. (35) BZ-Asn- i-Pr- H t-BuO-
19. (37) QC-Asn- -(CH2)4- t-BuO-
20. (38) QC-CNAIa- t-BuO-
BAD ORIGINAL
In the above Table, CBZ refers to benzyloxycarbonyl; QC refers to quinoline-2-carbonyl; PC refers to 2-pyridinemethoxycarbonyl; Asn refers to asparagine; Val refers to valine; Gin refers to glutamine and Thr refers to threonine, BZ refers to benzoyl, PIC refers to picolinyl and CNAIa refers to 3cyano-L-alanine.
These compounds have the ability to inhibit HIV-1 and HIV-2 proteases and anti-HIV antiviral properties at the concentration from 10 nM to 100 μΜ in acutely infected MT 2 and peripheral blood lymphocytes. Compounds No. 2, 7B, 8 and 17 have shown a similar or increased ability to inhibit HIV to AZT (a2idothymidine), with lower toxicity to the cells.
The HIV protease-inhibiting activity of representative compounds of the present invention has been tested by known methods (Brinkworth, R.I., et si., Biochem. 3iophys. Res. Commun. 176, 241, (1991); McLeod, D.A., et al., Bioorganic & Medicinal Chemistry Letters (1991) 653-658). In this test, a number of compounds described in the examples hereinabove have been found to inhibit HIV-1 protease with half-maximal inhibition occurring at inhibitor concentrations (IC^) of from sub nanomolar range to micromolar range, more typically, 3nM to 30pM.
The results of the above test compounds are presented in Table 2; TABLE 2: HIV Protease-inhibiting Activitv of Compounds of Formula (IV)
Compound No IC50 (nM)
2a 5.4 ± 0.54
7A 7.3 ±0.7
7B < 3.5
10 3300 ± 650
11 12.5 ± 3.2
The antiviral activity of representative compounds of the present invention has been determined at the Antivirals Laboratory, Fairfield Hospital, Fairfield, Victoria, Australia. In this test a stock solution of each compound was made in DMSO, then diluted in culture medium (RF 10) to 2x the final concentration required for test. The final concentration of DMSO was 1 % or below. Approximately 250,000 continuous lymphocytes of human origin (MT2 cells) or 750,000 human peripheral blood lymphocytes (PBLs) were exposed to dilutions of each test compound, then immediately infected with Human Immunodeficiency Virus type 1 (HIV) strain # 237228 (a clinical isolate obtained from a human source). The infectivity titers were expressed as tissue culture 50% infective dose (TCID5Q per ml) with 1 TCID50
BAD original corresponding to the amount of supernatant required to infect 50% of the replicate cell cultures. The 250 and 200 TCID5Q were used for MT2 and PBL cells respectively. The cell/drug/virus mixture was then incubated at
37OC/CC>2 in a 24-well microtitre plate. Fresh amounts of the appropriate dilution of each drug were added to both MT2 and PBL cultures at day 3. At day 6, the extent of HIV-specific Cytopathic effects (CPE) associated with each concentration of test compound in each of the cultures was rated according to the following scale:
MT2 cells PBLs
4 + : 75-100% of cells showing 3 + : good CPE
CPE
3 + : 50-75% of cells showing CPE 2 + : moderate CPE
2 +: 25-50% of cells showing CPE 1 + : low CPE
1+: 5-25% of cells showing CPE trace: minimal CPE
+ /-: less than 5% CPE Negative: no CPE Negative: no CPE
The activity of the compounds at each concentration was also assessed by their ability to inhibit viron-associated reverse transcriptase (RT) activity in the culture supernates. At the time of rating of CPE, supernatant fluids from each well were removed and RT activity measured using a standard assay. CPE ratings of negative, +/- (in MT2 cells) or trace (in PBLs), with greater than 95% inhibition of RT activity, was considered to represent IC-jqq (the concentration of compound at which the virus replication is inhibited). Control cultures included in each test were:
(a) HIV-infected cells in the absence of test compound.
(b) Uninfected cells in the absence of tested compound.
(c) Cell toxicity control consisting of uninfected cells treated with dilutions of test compound.
At the conclusion of each experiment, viable cells in these cultures,
BAD ORIGINAL A as determined by tryptan biue exclusion, were compared with the counts obtained in (b), above. Only concentrations which were non-toxic (not resulting in viable cell counts significantly reduced to those found in (bl) were used in determining the antiviral index (Al) of each test compound. The ability of compounds 1-20 to block the spread of acute HIV infection in lymphocytic cell lines is shown in Table 3
Table 3: Anti-HIV-1 Antiviral Properties of Compounds 1-20.
MT2 Ceils PBL Cells
No. •C iQQ (pM) Al IC100 tvM) Al
1. - 0(a) 1 nd
2a. O.'l 50 0.1 100
2b. 0.1 50 0.1 100
2b.A. O.Jiib) 100 0.01 1000
3. 1 5 1 5
4. 1 10 1 10
5. 1 < 10 1 < 10
6. 1 < 5 1 < 5
7A. 1 50 1 25
7B. 0.1 200 0.1 > 200
8. 0.1 > 100 0.1 > 100
9. 5 4 nd -
10. 25 1 nd -
11. 1 > 10 nd -
12. 1(b) 10 nd -
13. 1 50 1 > 50
14. 1 50 1 > 50
15. 1 100 1 200
16. 1 100 1 1
17. 0.1 100 0.1 200
18. 1 10 1 > 150
19. 1 10 0.1 200
20. 1 10 1 10
S 6 £ 0 0 0 dV
IC5Q; ICgo; nd = not done.
In order to further illustrate the present invention, the following specific examples are given, it being understood that these are intended as illustrative only and are in no way limitative of the invention.
BAD original ft
In these examples, melting points were taken on a hot stage apparatus and are uncorrected. Proton NMR spectra were recorded at 100 MHz or 300MHz on Perkin Elmer R32 or Bruker EM 300 spectrometers, respectively. Chemical shifts are ppm downfield from tetramethylsilane. Molecular weights of the compounds presented in Examples 1 to 23 were confirmed by electrospray mass spectrometry analysis, performed in the Department of Chemistry at La Trobe University, Melbourne. Thin layer chromotography (TLC) was performed on silica gel 60-F254 plates (Merck,. Compounds were visualized by ultraviolet light and/or 2% aqueous potassium permanganate io solution. The compositions (by volume) of the TLC solvent system were as follows: (A) = hexane/ethyl acetate 4:1; (B) = hexane/ethyl acetate 3:2; (C) = ethyl acetate; (D) = cnloroform/methanol 23:2.
EXAMPLE 1
O t-Butyl 3 -isopropvl-[(2R,3S)-2-hvdroxv-3-(phenylmethoxycarbonyl)arriino-415 pheny Ibutyllcarbazate
Step A: t-Butyl 3-isopropyl carbazate: The title compound can be prepared by method of Dutta et al., J.C.S. Perkin I 1975, 1712-1720 or by the following procedure: A mixture of 13.2 g (0.1 mol, of t-butyl carbazate and 6 g (0.103 mol) of acetone and 12.5 g (0.1 mol) of anhydrous magnesium sulfate in 100 ml of methylene chloride was stirred for 12 hr. at room temperature. After removal of the drying agent by filtration the filtrate was evaporated to dryness under reduced pressure to give 16.9 g (98% yield) of corresponding hydrazone melting 104-105°C after crystallization from cyclohexane. To a suspension of 2.04 g (0.094 mol, of lithium borohydride in 100 ml of dry THF, 12 ml (0.094 mol) of chlorotrimethylsilane was added under nitrogen at room temperature. After 30 min. of stirring,
13.45 g (0.078 mol) of hydrazone was slowly added at room temperature and stirring was continued for 2 hr. Then 50 ml of methanol was carefully added and the mixture was evaporated to dryness under reduced pressure.
The residue was partitioned between ether (150 ml) and water (50 ml). The organic phase was dried over anhydrous magnesium sulfate and filtered off. Dry hydrogen chloride was passed through the filtrate and the white solid formed was removed by filtration, washed with a fresh portion of ether and dried to give 10.5 g of hydrochloride salt of the title compound. This was transformed into a free base by partition between hexane (150 ml) and 20% aqueous potassium hydroxide. Yield 8.3 g (61%).
Step B: t-Butyl 3-lsopropyl-[(2R,3S,-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]carbazate: A mixture of 0.15 g (0.45 mmol)
AP 0 0 0 3 9 5
BAD ORIGINAL of N-CBZ-L-phenylalar.ine chioromethyl ketone and 1 ml of a saturated solution of sodium iodide in dry DMF was stirred for 15 min. at room temperature. To this, 0.074 g (0.47 mmol) of t-butyl 3-isopropyl carbazate was added followed by 0.095 g (1.13 mmol, of sodium bicarbonate. After 6 hours of stirring at room temperature, 0.051 g (1.3 mmol) of sodium borohydride was added end stirring was continued for an additional 30 min. The solution was diluted to 30 ml with ethyl acetate and washed with 2% aqueous potassium bisuifste solution, water and saturated aqueous sodium chloride solution, and then dried over anhydrous magnesium sulfate.
Evaporation of the sob ent under reduced pressure and purificaton of the residue by flash chromatography (silica gel; hexane/ethyl acetate 20:5, gave the title compound, melting at 118 - 119.5°C, in 49% yield; R(A, =0.11; R (5, =0.47; NMR (CDC:3) 1.0 (m, 6H, isopropyl CH3); 1.44 (s, 9H, t-butyl CH3); 2.62 (m, 2H, iuf./l CH2-1); 2.75 - 3.2 (m, 3H, butyl CH-3, CH2-4;
3.47 (m, 1H, isopropyl CH); 3.89 (m, 1H, butyl CH-2); 4.44 (broad s, 1H,
OH); 4.6 (broad m, 1H, NH); 5.03 (s, 2H, methoxy CH2); 5.3 (broad s, 1H, carbazate NH,; 7.23 (m, *0H, aromatic).
EXAMPLE 2 t-Butyl 3-?sopropyl-3-f(2R.3S)-2-hvdroxy-3-(N-quinaldoyl-L-valyl)amino20 4-phenvlbutvllcarbazate
Step A: N-Quinaldoy!-L-Va!ine: A mixture of 0.62 g (3.6 mmol) of quinaldic acid and 0.61 g (3.76 mmol, of 1,1'-carbonyldiimidazole in 1 ml of dry 1,4-dioxane was stirred for 30 min at room temperature. To this, a solution of 0.43 g (3.7 mmol) of L-valine and 0.1 55g (3.7 mmol, of lithium hydroxide in 1 ml of water was added and the resulting mixture was stirred vigorously at room temperature for about 4 hours. The mixture was diluted to 10 ml with water, cooled (ice-water bath), then acidified with 1N hydrochloric acid to pH about 3 and allowed to stand for 2 hours at 4°C.
The crystals which formed were removed by filtration, washed three times with 5 ml of cold water and dried under high vacuum over phosphorus pentoxide to give 0.75 g of the product. Yield = 76%, melting point 134 -136°C, NMR (DMSO-dg) 1.03 (d, 6H, val CH3); 2.3 (m, 1H, val CH-β); 3.35 (broad s, 1H, OH); 4.49 (q, 1H, val CH-a); 7.5 - 8.3 (m, 5H, aromatic,; 8.5 8.76 (m, 2H, aromatic, NH).
Step B: t-Butyl 3-isopropyl-3-[(2R,3S,-3-amino-2-hydroxy-4-phenylbutyl]carbazate: To a chilled solution of 0.113 g (0.24 mmol) of the product of Example 1 in 2 ml of methanol was added 0.1 g of 10% palladium on activated carbon under nitrogen, followed by 0.1 g of sodium borohydride.
fi 6 £ 0 0 0 dV
BAD ORIGINAL d
The reaction was allowed to warm to room temperature and stir for i hour, then catalyst was removed by filtration and washed with fresh portion of methanol. The combined filtrates were treated with 1 ml of 0.1 N aqueous solution of hydrochloric acid and evaporated to dryness under reduced pressure. The residue was treated with 5 ml of 0.1 N potassium hydroxide and the product was taken up with 30 ml of diethyl ether. The organic phase was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and evaporated under reduced pressure to give 0.0797 g (99% yield) of the Step B product, which was used in the next step io without further purification.
Step C: t-Butyl 3-isopropyl-3-[(2R,3S)-2-hydroxy-3-{N-quinaldoy!-t.-V0!yl)amino-4-phenylbutyl]carbazate: To a mixture of 0.0643 g (0.24 mmoi) cf ihe acid from Step A, 0.0797 g (0.235 mmol) of the the amine from Step 3, 0.032 g (0.24 mmol) of 1-hydroxybenzotriazole in 0.5 ml of anhydrous OMF was added 0.071 g (0.24 mmol, of 1-(3-dimethylaminopropyl,-3-ethy:carbodiimide methiodide. After stirring overnight at room temperature th? mixture was diluted to 30 ml with ethyl acetate and washed successiv?.iy with water, 5% aqueous sodium bicarbonate, 2% aqueous potassium bisulfate solution, and saturated sodium chloride solution and dried over anhydrous magnesium sulfate. Evaporation of the solvent under reduced pressure and purification of the residue by column chromatography {siiica gel, hexane/ethyl acetate 3:2, gave 0.091 g (65% yield, of the title compound, melting at 186 - 189°C: Rf (B) = 0.19; Rf (C, = 0.83; NMR (CDCI3) 1.0 (m, 12H, val and isopropyl CH3,; 1.71 (s, 9H, t-butyl CH3,; 2.3 (m, 1H, val CH25 B); 2.5 - 3.27 (m, 3H, butyl CH-3, CH2); 3.5 (m, 1H, isopropyl CH); 4.31 (m, 2H, val CH-α, OH); 5.43 (broad s, 1H, carbazate NH); 6.22 (broad d, 1H, butyl NH); 6.7 - 8.73 (m, 12H, aromatic, NH).
EXAMPLE 3 t-Butyl 3-isopropvl-3-f(2R,3S)-2-hvdroxv-3-(N-quinaldovl-L-asparaqiny!)ami,no30 . 4-phenylbutyllcarbazate
Step A: N-Quinaldoyl-L-asparagine: When L-asparagine was substituted for L-valine in Step A of Example 2, the identical process afforded the title compound, melting at 200 - 203°C, in 85% yield, NMR (DMSO-dg, 3.0 (rrt,
2H, asn CH2); 5.0 (m, 1H, asn CH-a); 6.3 (broad s, 1H, OH); 6.55 (broad s,
1H, NH2); 7.3 (broad s, 1H, NH2); 7.55 - 8.6 (m, 6H, aromatic); 9.22 (d, 1H,
NH).
Step B: t-Butyl 3-isopropyl-3-[(2R,3S)-2-hydroxy-3-(N-quinaldoyl-Lasparaginyl)amino-4-pheny!butyl]carbazate: To a stirred solution of the
S 6 £ 0 0 0 dV
BAD ORIGINAL &
product of Step A (0. H 1 g: 9.386 mmol), the product of Example 2, Steo S (0.13022 g; 0.386 mmo!', benrctriazoi-l-yloxytrisidimethyl-amino)phosphonium hexafluorcchosphate (0.235 g; 0.46 mmol) and 1-hydroxybsnzotriazole (0.052 g: 0 3 ·Λ mrr.ol) in 1 ml of anhydrous DMF was added, N,N-diisopropy!ethyio.~i;nj (0..) 1 ml; 1.38 mmol). After stirring for 12 hours at room temperature the reacccn was diluted to 30 ml with ethyl acetate and washed with water, 2% potassium bisulfate, 5% sodium bicarbonate and saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate. Evaporation of the solvent under reduced pressure and purification of the reside0 by column chromatography (silica gel, ethyl acetate) gave 0.152 g (35% yield) of the title product melting at 109 i14°C; Rf(C) = 0.36; Rf(D) - 0.37; NMR (CDCI3) 1.0 (m, 6H, val, isopropyl CH3); 1.42 (s, 9H, t-butyl Cri^·; 2.5 - 3.1 (m, 7H, asn CH2, butyl CH?-'. ,-4, CH-3); 3.44 (m, 1H, isopor/l CH); 4.21 (m, 1H, butyl CH-2); 4.55 (s, i’-i, OH); 4.94 (m, 1H, asn CH-c; 5 4 - 6.2 (m, 3H, amide); 6.7 - 8.4 (m, 11H, aromatic); 9.25 (m, 1'H,
EXAMPLE 4
1-(2-pyridyl)methoxycnrboi;ylarithr3nitoyl-2-i(2R,3S)-2-hvdroxv-3-(Nquinaldoyl-L-3SparaqinyD3mino-4-phenylbutvll-2-isopropyl-hydrazine Step A: (2-Pyridyl)methoxycarbonylanthranilic acid: Phosgene was bubbled through a solution of 10 g (66 mmo!) of methylanthranilate in 15 m! of anhydrous toluene for 2 hours at reflux. Then the solvent was distilled off under reduced pressure to give 11.7 g (100%) of 2-methoxycarbonylphenylisocyanate; NMR (CDCI3) 3.89 (s, 3H, CH3); 7.0 - 7.63 (m, 3H, phenyl H-3,-4,-5); 8.0 (dd, 1H, phenyl H-6). This was converted to the title compound, in 34% overall yield, by condensation with an equimolar amount of 2-pyridylcarbinol followed by saponification of the resulting ester with 1 N sodium hydroxide and acidification of the reaction mixture to pH 4. The crude product was purified by crystallization from ethyl acetate; melting point = 172 - 175°C; NMR (DMSO-dg) 5.2 (s, 2H, methoxy CH2); 6.8 - 8.8 (m,
9H, aromatic, NH); 10.8 (broad s, 1H, OH).
Step B: 2-[(2R,3S)-2-hydroxy-3-(N-quinaldoy!-L-asparaginyl)amino-4phenylbutyl]-2-isopropyl-hydrazine: Hydrogen chloride gas was bubbled through the solution of 0.1 g (0.165 mmol) of product of Example 3 in 10 ml of 1 % solution of methanol in methylene chloride for 30 min at room temperature. After washing the excess of HCl with nitrogen the solvent was removed under reduced pressure to give 0.089 g (100%) of the title compound as a white solid.
BAD ORIGINAL d
Step C: 1-(2-pyridyl)methoxycarbony!anthrani!oyl-2-[{2R,3S,-2-hydroxy3-(N-quinaIdoyl-L-asparaginyl)amino-4-phenylbutyl]-2-isopropyI-hydrazine:
Coupling the products of Step A and B, using the general procedure outlined in Example 3, Step B, gave the title compound in 24% yield, after purification by column chromatography (silica gel, ethyl acetate); melting point = 96 112°C; Rf (C) = 0.13 ; Rf (D) = 0.36; NMR (CDCI3, 1.18 <m, 6H, isopropyl CH3); 1.8 - 3.4 (m, 8H, asn CH2, butyl CH2-1,-4, CH-3, OH); 3.6 (m, 1H, isopropyl CH); 4.2 (m, IH, butyl CH-3); 4.5 - 5.18 (m, 2H, asn CH-a, hydrazide NH); 5.35 (s, 2H, methoxy CH2); 5.3 - 6.5 (broad m, 2H, asn
NH2); 6.8 - 8.8 (m, 20H, aromatic, butyl NH); 9.14 (m, 1H, asn NH,; 10.36 (s, 1H, anthr. NH).
EXAMPLE 5 t-Butyl 3-isopropvl-3-[(2-oxo-3(S)-(N-quinaldoyl-L-asparaqinyl)amino-4phenvlbutyllcarbazate
To a mixture of 0.0533 g (0.088 mmol) of the product of Example 3 and 0.049 g (0.31 mmol) of sulfur trioxide pyridine complex in 1 ml of anhydrous DMSO 0.043 ml (0.31 mmol) of triethylamine was added. After stirring for 45 min at room temperature the reaction mixture was poured on ice and allowed to warm to room temperature. The precipitate which formed was removed by filtration, washed with water and dried overnight in vacuo to give 0.044 g {83% yield, of the title compound which was further purified by crystallization from the aqueous methanol; melting point = 146 - 150°C; Rf (D, = 0.32; NMR (CDCI3) 1.0 (d, 6H, isopropyl CH3); 1.38 (s, 9H, t-butyl CH3); 2.5 - 3.3 (m, 5H, asn CH2, butyl CH2, isopropyl CH,; 3.7 (s, 2H, butyl
CH2); 4.6 - 5.3 (m, 2H, asn CH, butyl CH-3); 5.6 (broad s, 1H, NH); 6.09 (broad m, 2H, 2 x NH); 6.9 - 8.4 (m, 12 H, aromatic, NH); 9.2 (broad d, 1H, asn NH).
EXAMPLE 6 t-Butyl 3-(1-methyl-3-phenylpropen-3-yl)-3-f(2R and S, 3S)-2-hydroxy-330 (ohenvlme thoxvcarbonvi)amino-4-phenvlbutyllcarbazate
Step A: 2{R,S)-3(S)-1,2-Epoxy-3-phenylmethoxycarbonyIamino-4-phenylbutane; To the solution of 6 g (18 mmol) of N-CBZ-L-phenylalanine chloromethyl ketone in 30 ml of 50% methanolic tetrahydrofuran was added 0.68 g of sodium borohydride. After stirring for 30 min at room temperature the mixture was carefully acidified with 1N hydrochloric acid and evaporated to dryness under reduced pressure. The residue was diluted to 50 ml with methylene chloride, washed with water and saturated aqueous sodium chloride and dried over anhydrous magnesium sulfate. Evaporation gave
BAD ORIGINAL ft
6.02 g (100%) of 2(R,S)-3(S)-1-chloro-2-hydroxy-3-phenylmethoxycarbonylamino-4-phenylbutane, as a white solid. This was dissolved in 50 ml of isopropanol and 9 ml of 2N methanolic potassium hydroxide was added at room temperature. After stirring for 1 hour at room temperature the solvent was removed under reduced pressure and the residue was partitioned between 50 ml of ethyl acetate and 20 ml of water. The organic phase was washed with saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate and evaporated to dryness to give 5.3 g (99% yield) of the title compound as the predominantly 2(S) stereoisomer as determined io from relative integration of erythro-NCH (3.74 ppm; 72%) and threo-NCH (4.2; 28%); NMR (CDCI3) 2.42 - 3.17 (m, 5H, butane CH2-1,-4, CH-2); 3.74 (m, 0.72H, butane CH-3); 4.2 (m, 0.28H, butane CH-3); 4.73 (broad m, 1H, NH); 5.08 (s, 2H, methoxy CH2); 7.3 (m, 10H, aromatic).
Step B: t-Butyl 3-(1-methyl-3-phenyIpropen-2-yl)carbazate: This compound was prepared by the method of Ghali et al. (J. Org. Chem., 1981, 46. 5413 - 5414) in about 65% overall yield, from trans-4-phenyl3-buten-2-one and t-butyl carbazate, after crystallization of the crude product from hexane; melting point = 76 - 79°C; NMR (CDCI3) 1.24 (d, 3H, CH3);
1.45 (s, 9H, t-butyl CH3); 3.78 (m, 2H, propenyl CH-1, carbazate NH-3); 5.8
- 6.29 (m, 2H, carbazate NH-2, propenyl CH-2); 6.53 (d, 1H, propenyl CH-3);
7.3 (m, 5H, aromatic).
Step C: t-Butyl 3-(1-methyl-3-phenylpropen-3-yl)-3-[(2R and S, 3S)-2hydroxy-3-(phenyImethoxycarbonyl)amino-4-phenylbutyl]carbazates: 0.57 g of epoxide from Step A in about 15 ml of anhydrous ether was added at room temperature to a vigorously stirred suspension of 8 g of alumina (E. Merck I) impregnated with 1 g (3.81 mmol) of the product of Step B. The stirring was continued for 16 hours and the catalyst was removed by filtration and washed with ethyl acetate (3 x 25 ml). The combined filtrates were evaporated to dryness under reduced pressure and the residue was separated and purified by column chromatography (silica gel, hexane/ethyl acetate 4:1). The product fractions were evaporated in vacuo to give the 2R,3S isomer (0.298 g; 28%) and the 2S,3S isomer (0.1 g; 9%) of the title compound as a white solid.
Isomer 2R,3S: melting point = 101 - 104°C; Rf (A, = 0.19; NMR (CDCI3,
1.27 (dd, 3H, CH3); 1.42 (s, 9H, t-butyl CH3); 2.67 (m, 2H, butyl CH2-1);
3.0 (m, 2H, butyl CH2-4); 3.5 (rn, 2H, propenyl CH-1, butyl CH-3); 3.91 (m, 1H, buty, CH-2); 4.4, 4.82, 5.38 (broad multiplets, 3 χ H, amide NH, OH);
5.0 (s, 2H, methoxy CH2, 6.09 (dd, 1H, propenyl CH-2); 6.5 (d, 1H,
S 6 £ 0 0 0 dV bad original propenyl CH-3); 7.22 (m, 15H, aromatic).
Isomer 2S,3S: melting point = 128 - 130°C; Rf (A) = 0.26; NMR (CDCI3)
1.22 (m, 3H, CH3); 1.4 (s, 9H, t-butyl CH3); 2.55 (broad m, 2H, butyl CH2-D; 2.95 (d, 2H, butyl CH2-4); 3.5 (m, 3H, propenyl CH-2, butyl CH-2,-3); 4.44 (m, 1H, OH); 5.05 (m, 2H, methoxy CH2); 5.34 (m, 2H, NH); 6.08 (dd, 1H, propenyl CH-2); 6.5 (d, 1H, propenyl CH-3); 7.3 (m, 15H, aromatic).
EXAMPLE 7 t-Butvl 3-(1-methvl-3-phenvlpropvl)-3-f(2R,3S)-2-hvdroxv-3-(N-quinaldoyl-Lasparaqinvl)amino-4-phenylbutvl]carbazate
Step A: t-Butyl 3-( 1-methyl-3-phenylpropyl)-3-((2R,3S)-2-hydroxy-3amino-4-phenylbutyl]carbazate: This was prepared in 98% yield by hydrogenolysis of the isomer 2R,3S of the product of Example 6, Step C, performed as described in Example 2, Step B, as white solid.
Step B: t-Butyl 3-(1-methyl-3-phenylpropyl)-3-((2R,3S)-2-hydroxy-3-(Nquinaldoyl-L-asparaginyl)amino-4-phenyIbutyl]-carbazate: The condensation of the amine from Step A (0.0835 g; 0.195 mmol) with
N-quinaldoyl-L-asparagine (Example 3, Step A) (0.0563 g; 0.196 mmol), under condition given in Step B of Example 3, gave 0.11 g (81 % yield) of the title compound after purification by column chromatography (silica gel, chloroform/methanol 23:2); melting point = 141 - 143°C; Rf (C) = 0.53, Rf (D) = 0.38; NMR (CDCI3) 0.7 - 2.1 (m, 15H, CH3, t-butyl CH3, propyl CH2-2, OH); 2.4 - 3.26 (m, 8H, butyl CH2-1, -4, asn CH2, propyl CH2-3);
3.5 (m, 1H, propyl CH-1); 4.22 (m, 1H, butyl CH-3); 4.7 (m, 1H, carbazate NH); 4.95 (m, 1H, asn CH-a); 5.24 - 6.4 (m, 3H, NH2, NH); 6.5 - 8.5 (m, 16H, aromatic); 9.14 (d, 1H, asn NH).
EXAMPLE 8 cis-1,6-3-t-Butoxycarbonvl-4-((2RS,3S)-2-hvdroxv-3-(phenylmethoxvcarbonvl)amino-4-phenylbutvn-3.4-diaza-bicvclo-[4.4.0]decane
Step A: cis-1,6-3-t-Butoxycarbonyl-3,4-diaza-bicyclo[4.4.0]-decane:
Cis-1,2-cyclohexanedimethanol was converted quantitatively to cis-1,2cyclohexanedimethyliodide by the general method [Vogel's Textbook of Practical Organic Chemistry, 4th Ed. p. 393, Longman Group Limited, London 1978). An alkylation of 1-benzyloxycarbonyl-2-t-butoxycarbonylhydrazine (Dutta et al., J.C.S. Perkin I, 1975, 1712 - 1720) with cis-1,2-cyclohexanedimethyliodide, in the presence of two equivalents of sodium hydride by the method of Dutta et al (J.C.S. Perkin I, 1975, 1712 - 1720) gave cis-1,6-4-benzyloxycarbonyl-3-t-butoxycarbonyl-3,4-diazabicyclo[4.4.0]5 6 £ 0 0 0 dV
BAD ORIGINAL decane in 24% yield, after purification on column chromatography (silica gel, hexane); melting point = 68 - 69.5°C; NMR {CDCI3) 1.0 - 2.2 (m, 19H,
CH2-7,8,9,10, CH-1,6); 3.15 (m, 2H, CH2-5); 3.82 (m, 2H, CH2-2); 5.11 (m,
2H, benzyl CH2);7.3 (s, 5H, aromatic). This was converted to the title compound in 95% yield by hydrogenolysis, performed as described in
Example 2, Step B; melting point - 55 - 63°C; NMR (CDCI3) 1.0 - 2.05 (m, 19H, CH2-7,8,9,10, CH-1,6); 2.82 (m, 2H, CH2-5); 3.33 (m, 2H, CH2-2),
4.0 (broad s, 1H, NH).
Step B: cis-1,6-3-t-Butoxycarbonyl-4-[(2RS,3S)-2-hydroxy-3-(phenylmethoxy10 carbonyl)amino-4-phenylbutyl]-3,4-diaza-bicyclo-[4.4.0]decane: When the product of Step A was substituted for t-butyl 3-(1-methyl-3-phenylpropen-2yDcarbazate in Example 6, Step C, the identical process afforded the title compound, melting at 98 - 103°C, in 42% yield, after purification on column chromatography (silica gel, hexane/ethyl acetate 4:1); Rf (A) = 0.2, 0.3; Rf (B) = 0.55, 0.63; NMR (CDCI3) 1.0 -2.18 (m, 19H, decane CH2-7,8,9,1O,
CH-1,6, t-butoxy CH3); 2.42 (m, 2H, decane CH2-5); 2.78 - 4.5 (m, 9H, butyl CH2-1,4, CH-2,3, decane CH2-2, OH); 4.8 (broad m, 1H, NH); 5.0 (s, 2H, methoxy CH2); 7.22 (m, 10H, aromatic).
EXAMPLE 9 c?s-1.6-3-t-Butoxvcarbonvl-4-f(2RS,3S)-2-hvdroxy-3-(N-quinaldovl-L-valvl)amir>o-4-phenvlbutvn-3,4-diaza-bicvclof4.4.0)decane
When the product of Example 8 is substituted for t-Butyl 3-isopropyl-3[(2R,3S)-2- hydroxy-3-(phenylmethoxycarbonyl)amino-4phenylbutyDcarbazate in Example 2, the identical process afforded the title compound in 52% yield, after purification by column chromatography (silica gel, hexane/ethyl acetate 3:2); melting point = 95 - 101 °C; Rf (B) = 0.32;
Rf (C) = 0.85; NMR (CDCI3) 0.64 - 1.93 (m, 25H, val CH3, decane CH2-7,8,9,10, CH-1,6, t-butoxy CH3); 2.38 (m, 3H, decane CH2-5, val CHS); 2.73 - 3.82 (m, 7H, decane CH2-2, butyl CH2-1,4, CH-3); 3.82 - 5.35 (m, 3H, val CH-oc, butyl CH-2, OH); 6.0 - 9.0 (m, 13H, aromatic, NH).
EXAMPLE 10 cis-1,6-3-t-Butoxvcarbonvl-4-f(2RS,3S)-2-hvdroxv-3-(N-Quinaldovl-Lasparaqinvl)amino-4-phenvlbutvl1-3.4-diaza-bicvclof4.4.0)decane
According to Example 2, Step B, the product of Example 8 was converted quantitatively to cis-1,6-3-t-butoxycarbonyJ-4-[(2RS,3S)-2-hydroxy-3-amino-4-phenylbutyl]3,4-diaza-bicyclo[4.4.0]decane. This material was coupled with N-quinaldoylL-asparagine (Example 3, Step A) by process identical to Example 3, Step B bad original to give the title compound in 52% yield; melting point = 111-114°C; Rf (C) = 0.44; Rf (D) = 0.46; NMR (CDCI3) 1.0 - 2.2 (m, 19H, decane CH2-7,8,9,10, CH-1,6, t-butoxy CH3); 2.2 - 3.83 (m, 11H. decane CH2-2,5, butyl CH2-1,4, CH-3); 4.13 (m, 2H, butyl CH-2, OH); 4.95 (m, 1H, asn CH); 5.73, 6.24 (s, s, 2H. NH2); 6.7 - 7.33 (m, 6H, aromatic, NH); 7.4 - 8.42 (m, 6H, aromatic); 9.2 {broad m, 1H, NH).
EXAMPLE 11 cis-1.6-3-t-Butoxycarbonvl-4-[(2RS,3S)-2-hvdroxv-3-fN-(2-pyridyl)methoxvcarbonYl-L-valyl1amino-4-phenvlbutvl1-3.4-diaza-bicvclof44.01decane
Step A: N-(2-Pyridyl)methoxycarbonyl-L-valine: An equimolar mixture of (2-pyridyl)carbinol (3 g) and methyl L-2-isocyanato-3-methylbutanoate (4.32 g) (Fankhauser P. et al., Helv. Chim. Acta, 1970, 2298 - 2313) was stirred for 12 hours at 80 - 90°C under nitrogen to give 7.32 g (100%) of N-(2-pyridyl)methoxycarbonyl-L-valine methyl ester as a colorless syrup; NMR (CDCI3) 0.94 (m, 3H, val CH3); 2.17 (m, 1H, val CH-p); 3.71 (s, 3H, OCH3);
4.27 (m, 1H, val CH-a); 5.18 (s, 2H, CH2); 5.43 (m, 1H, NH); 6.85 - 7.82 (m, 3H, aromatic); 8.45 (m, 1H, aromatic). This was diluted to 25 ml with methanol and 6.04 ml of 5 M aqueous potassium hydroxide was added. The resulting mixture was stirred for 1 hour at reflux, then cooled to room temperature and evaporated to dryness in vacuo. The residue was diluted to 25 ml with water and washed with ether. The aqueous phase was cooled in an ice bath and acidified to pH = 5 and allowed to stay overnight at 4°C.
The resultant precipitate was filtered off, washed with small portions of cold water (3x15 ml) and dried in vacuo over phosphorous pentoxide to give
4.92 g (71 % yield) of the title compound melting at 116 - 118°C; NMR (DMS0-d6) 0.93 (d, 6H, val CH3); 2.1 (m, 1H, val CH-β); 3.4 (broad s, 1H, OH); 3.93 (m, 1H, val CH-a); 5.13 (s, 2H, CH2); 7.17 - 8.0 (m, 4H, aromatic, NH); 8.5 (m, 1H, aromatic).
Step B: cis-1,6-3-t-Butoxycarbonyl-4-[(2RS,3S)-2-hydroxy-3-[N-(2py ridyl)methoxyca rbonyl-L-valyl] a mino-4-phenyIbu tyl]-3,4-diaza-bicyclo [4.4.0]decane:
When the product of Step A is substituted for N-quinaldoyl-Lasparaglne in Example 10, the identical process afforded the title compound, melting at 82 - 87°C, in 38% yield after purification under the conditions given in Example 9; R^ (B) = 0.08; R^ (C) = 0.64; R^ (D) = 0.66; NMR (CDCI3) 0.82 (m, 6H, val CH3); 1.05 - 2.73 (m, 22H, decane
CH2-5,7,8,9,10, CH-1,6, t-butoxy CH3, val CH-β); 2.73 - 4.6 (m, 9H, butyl CH2-1,4, CH-2,3, decane CH2-2, val CH-a); 5.05 - 5.5 (m, 3H, CH2, OH);
BAD ORIGINAL &
5.5 - 6.78 (m, 2H, NH); 7.0 - 7.9 (m, 8H, aromatic); 8.57 (m, 1H, aromatic).
EXAMPLE 12 cis-1,6-3-t-Butoxycarbonvl-4-K2RS,3S)-2-hvdroxv-3-(N-quinaldoyl-Lqlutaminvl)amino-4-phenvlbutvl)-3,4-diaza-bicvclo[4.4.01decane 5 Step A: N-Quinaldoyl-L-Glutamine: When L-glutamine was substituted for L-valine in Step A of Example 2, the identical process afforded the title compound, melting at 188 - 190°C, in 72% yield; NMR (CDC^/DMSO-dg 1:1) 2.34 (m, 4H, gin CH2); 4.7 (m, 1H, gin CH-α); 6.3, 7.15 (broad ss, 2H, NH2); 7.4 - 8.51 (m, 7H, aromatic OH); 8.82(d, 1H, NH).
Step B: cis-1,6-3-t-Butoxycarbonyl-4-((2RS,3S)-2-hydroxy-3-INquinaldoyl-L-glutaminyl]amino-4-phenylbutyl]-3,4-diaza-bicyclo[4.4.0]decane: When the product of Step A is substituted for N-quinaldoyl-L-asparagine in Example 10, the identical process afforded the title compound, melting at 106 - 115°C, in 18% yield; Rf (C) = 0.27; Rf (D) = 0.30; NMR (CDCI3) 0.8
- 2.7 (m, 26H, decane CH2-7,8,9,10, CH-1,6, gin CH2. t-butoxy CH^, butyl
CH-3); 2.7-3.8 (m, 6H, decane CH2-2.5, butyl CH2-4); 4.36 (m, 1H, butyl CH-2); 4.6 (m, 1H, gin CH); 5.1 (broad s, 1H, OH); 5.4 (m, 1H, NH); 6.07,
6.6 (d,d, 2H, NH2); 6-8 - 8.5 (m, 11H, aromatic); 8.8 (m, 1H, gin NH).
EXAMPLE 13 cis-1,6-3-t-Butoxycarbonvl-4-f(2RS,3S)-2-hvdroxv-3-(N-quinaldovl-L-threonyl)amino-4-phenylbutvlf-3,4-diaza-bicvcloi4.4.0)decane
Step A: N-Quinaldoyl-L-threonine: When L-threonine was substituted for
L-valine in Step'A of Example 2, the identical process afforded the title compound, melting at 184 - 185°C, in 74% yield; NMR (CDCIg/DMSO-dg
1:1) 1.29 (m, 3H, CH3); 4.5 (m, 1H, thr CHB); 4.68 (dd, 1H, thr CH-a); 7.4
-9.27 (m, 9H, aromatic, acid OH, 2-OH, NH).
Step B: cis-1,6-3-t-Butoxycarbonyl-4-[(2RS,3S)-2-hydroxy-3-(Nquinaldoyl-L-threonyl)amino-4-phenylbutyl]-3,4-diaza-bicyclo[4.4.OJdecane: When the product of Step A is substituted for N-quinaldoyl-L-asparagine in
Example 10, the identical process afforded the title compound, melting at 102 - 112°C, in 36% yield, Rf (C) = 0.72; Rf (D) = 0.61, 0.7; NMR (CDCI3, 1.0 - 2.75 (m, 25H, t-butoxy CH3, decane CH2-7,8,9,10, CH-1,6, butyl CH2-4, OH); 2.75 - 4.0 (m, 8H, decane CH2-2,5, butyl CH2-4, OH); 4.0 - 4.7 (m, 3H, thr CH-α, butyl CH-3); 6.5 - 7.4 (m, 6H, aromatic, NH); 7.4 - 8.5 (m,
6H, aromatic); 8.8 (m, 1H, thr NH).
BAD ORIGINAL
EXAMPLE 14
2-t-Butoxycarbonyl-3-i(2RS,3S)-2-hydroxy-3-(phenvlmethoxvcarbonvl)amino4-phenylbutvl]-2,3-diaza-bicvclo(2.2.1lhept-5-ene
Step A: 2-t-Butoxycarbonyl-3-phenylmethoxycarbonyl-2,3-diaza-bicyclo5 [2.2.1]hept-5-ene: To a stirred mixture of 1 g (4.34 mmol) of 1-benzyloxycarbonyl-2-t-butoxycarbonylhydrazine (Dutta et al., J.C.S. Perkin I, 1975, 1712 - 1720) in 30 ml of anhydrous methylene chloride 1.55 g (8.7 mmol) of N-bromosuccinimide was added at 0°C and the stirring was continued for 1 hour with external cooling in an ice bath. The reaction mixture was washed iq with 10% aqueous sodium thiosulfate solution and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and evaporated to dryness in vacuo. The residue was redissolved in 15 ml of anhydrous ether, 0.57 g (8.7 mmol) of freshly distilled cyclopentadiene was added and the mixture was allowed to stay for 1 hour at room temperature. Evaporation to 15 dryness under reduced pressure gave O.77g (54% yield) of the title product as a colorless syrup; NMR (CDCI3) 1.44 is, 9H, t-butoxy CH3); 1.7 (m, 2H, CH2-7); 5.06 (m, 2H, CH-1,4); 5.15 (s, 2H, methoxy CH2); 6.4 (m, 2H, CH-5,6); 7.24 (m, 5H, aromatic).
Step B: 2-t-Butoxycarbonyl-3-[(2RS,3S)-2-hydroxy-3-(phenylmethoxy20 carbonyl)amino-4-phenylbutyl]-2,3-diaza-bicyclo[2.2.1]-hept-5-ene: A mixture of 0.2 g (0.6 mmol) of the product of Step A and 0.8 ml of IN aqueous solution of potassium hydroxide in 5 ml of methanol was refluxed under nitrogen for 4 hours. The resulting mixture was partially evaporated, diluted to 10 ml with water and extracted with diethyl ether (3x10 ml). The combined organic phase was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and evaporated to dryness. The residue was purified by column chromatography (silica gel; hexane/ethyl acetate 3:2) to give 0.05 g (42% yield) of 2-t-butoxycarbonyl-2,3-diazabicyclo(2.2.1 )hept-5-ene. This material (0.049 g, 0.25 mmol) was dissolved in 2 ml of isopropanol containing 0.0744 g (0.25 mmol) of 2(R,S)-3(S)-1,2epoxy-3-phenylmethoxycarbonylamino-4-phenylbutane (Step A of Example 6) and the resulting mixture was stirred for 15 hours at 80 ± 5°C under nitrogen. The mixture was cooled to room temperature, evaporated to dryness in vacuo and purified by column chromatography (silica gel hexane/ethyl acetate 4:1) to give 0.054 g (44% yield) of title product;
melting point = 111 - 113°C; Rf (A) = 0.07; Rf (B) = 0.31; NMR {CDCI3)
1.43 (s, 9H, t-butoxy CH3); 1.8 (m, 2H, CH2-7); 2.4-3.15 (m, 4H, butyl CH2-1,4); 3.2 - 4.2 (m, 3H, butyl, CH-2,3, OH); 4.5 - 5.33 (m, 5H, CH-1,4, bad original methoxy CH2, NH); 6.2 - 6.6 (m, 2H, CH-5,6); 7.2 (m, 10H, aromatic).
EXAMPLE 15
2-1-Βιηοχνο3Γί>οηγΙ-3-Η2Π5,35)-2-ΚνάΓθχν-3-(ρ1ΐ6ηνΐΓηβΐΗοχνο3ΓϋοηνΠ3Γηίηο4-phenylbutvl1-2,3-diaza-bicyclof2.2.11heptane 5 When the product of Step A of Example 14 is substituted for cis-1,6-4benzyloxy-carbonyl-3-t-butoxycarbonyl-3-4-diaza-bicyclo[4.4.0]decane in Example 8, a similar process afforded the title compound in 31 % yield; melting point = 119 - 126°C; Rf (A) = 0.12; Rf (B) = 0.34, 0.39; NMR (CDCI3, 1.2 - 2.1 (m, 15H, t-butoxy CH3, CH2-5,6,7); 2.5 - 3.2 (m, 4H, 10 butyl CH2-1,4); 3.2 - 4.4 (m, 4H, butyl CH-2,3, CH-1,6); 4.7 - 5.5 (m, 4H, methoxy CH2, NH, OH); 7.26 (m, 10H, aromatic).
EXAMPLE 16
2-t-Butoxycarbonyl-3-f(2RS, 3S)-2-hvdroxy-3-fN-(2-pyr?dvl)-methoxvcarbonvlL-valvHamino-4-phenvlbutyl1-2,3-diaza-bicyclof2.2.11- heptane 15 According to Example 2, Step B the product of Example 15 was converted quantitatively to 2-t-butoxycarbonyl-3-[(2RS, 3S)-3-amino-2hydroxy-4-phenylbutylJ- 2,3-diaza-bicyclo(2.2.1]heptane. This material was coupled to N-(2-pyridyl)methoxycarbonyl-L-valine (Example 11, Step A) by process identical to Example 3, Step B to give the title compound in 51% yield: melting point = 73 - 77°C; (C) = 0.45; R^ (D) = 0.49; NMR
... (CDCI3) 0.7 - 1.0 (m, 6H, val CH3); 1.25 - 2.15 (m, 1 6H, t-butoxy CH3, val CH-β, CH2-5,6,7); 2.55 - 3.1 (m, 4H, butyl CH2-1,4); 3.3 - 3.7 (butyl CH-2,3); 3.91 (m, 1H, val CH-a); 4.1 - 4.4 (m, 2H, CH-1,4); 4.9 - 5.4 [m,
4H, methoxy CH2 (s, 5.26), OH, NH]; 6.6 (m, 1H, NH); 7.26, 7.7, 8.57 (m,
7H, 1H, 1H, aromatic).
EXAMPLE 17
2- fN-(1S)(2-methvl-1-methoxvcarbonvlpropvl)carbamovl1-3-F(2RS,3S)-2hvdroxv-3-fN-(2-pvridvl)methoxv-L-valvl1amino-4-phenvlbutvl1-2.3-diazabicvclof2.2.11heptane
According to Example 4, Step B, the product of Example 16 was converted quantitatively to the hydrochloride salt of 3-[(2RS, 3S)-2-hydroxy3- (N-(2-pyridyl)-methoxy -L-valyl]amino-4-phenylbutyl]-2,3-diaza-bicyclo[2.2.1]heptane. This material (0.06 g; 0.113 mmol) and an equimolar amount of methyl L-2-isocyanato-3-methyl-butanoate were dissolved in 0.4 ml of ethanol free chloroform and to it was added 0.031 ml of diisopropylethylamine. The resulting mixture was allowed to stay for 12 hours at room temperature, under nitrogen, then diluted to 15 ml with ethyl acetate and washed with water and dried over magnesium sulfate.
AP 0 0 0 3 9 5
BAD ORIGINAL
Evaporation {n vacuo and purification by column chromatography (silica gel, ethyl acetate, gave 0.051 g (66%, of the title compound; melting point = 79
- 84°C, Rf(C, = 0.2; Rf(D) = 0.46; NMR(CDCI3); 0.5 -1.0 (m, 12H, val
CH3); 1.0 - 2.5 (m, 10H, val CH-β, butyl CH2-1, CH2-5,6,7); 2.5 - 3.33 (m, 5 3H, butyl CH2-4, CH-3); 3.33 - 4.05 (m, 6H, val CH-α, CH-4, 0CH3); 4.05 5.5 (m, 6H, butyl CH-3, OH, CH-1, NH, methoxy CH2); 5.82 - 6.7 (m, 2H, val NH); 6.9 - 7.9, 8.6 (m, m, 8H, 1H, aromatic).
EXAMPLE 18
2-t-Butoxycarbonyl-3-f{2RS. 3S)-2-hvdroxv-3-(N-Quinaldovl-L-asparaqinvl)10 amino-4-phenylbutyll-1,2,3,4-tetrahvdrophthalazine
Step A: 2-t-Butoxycarbonyl-3-((2RS, 3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]-1,2,3,4-tetrahydrophtalazine: To a mixture of 0.19 g (1.11 mmol) of hydrochloride salt of 1,2,3,4-tetrahydrophthalazine (Groszkowski and Wesolowska, Arch. Pharm, (Weinheim) 314, 880 (1981)] 15 and 0.23 g (1.05 mmol) of di-tert-butyl dicarbonate in 5 ml of chloroform was added 0.147 ml (1.05 mmol) of triethylamine under nitrogen. After stirring for 5 hours at room temperature the mixture was diluted to 30 ml with ethyl acetate, washed with water and saturated aqueous sodium chloride solution and dried over magnesium sulfate. Evaporation of the solvent in vacuo and
2o purification of the residue by chromatography on silica gel (hexane/ethyl acetate 4:1) gave 0.0921 g (37%, of 2-t-butoxycarbonyl-1,2,3,4-tetrahydrophthalazine; NMR (CDCI3) 1.5 (s, 9H, t-butoxy CH3); 4.0 (s, 2H, CH2-4);
4.47 (broad s, 1H, NH); 4.64 (s, 2H, CH2-1); 6.95 (m, 4H, aromatic). When this material was substituted for 2-t-butoxy-carbonyl-2,3-diazabicyclo[2.2.1 ]25 hept-5-ene in Step B of Example 14 a similar process afforded the title compound in 24% yield after purification on column chromatography (alumina, chloroform/ethyl acetate 95:5); melting point = 68 - 71 °C; NMR (CDCI3, 1.5 (s, 9H, t-butoxy CH3); 2.18 - 3.15 (m, 4H, butyl CH2-1,4); 3.3 5.5 (m, 10H, butyl CH-2,3, CH2-1,4, methoxy CH2, OH, NH); 7.22 (m, 14H, 30 aromatic,.
Step B: 2-t-Butoxycarbonyl-3-[(2RS, 3S)-2-hydroxy-3-(N-quinaldoyl-Lasparaginyl)amino-4-phenylbutyl]-1,2,3,4-tetrahydrophthalazine: When the product of Step A is substituted for cis-1,6-3-t-Butoxycarbonyl-4-[(2RS,3S)-2hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]-3,4-diaza35 bicyclo[4.4.0]decane in Example 10 the identical process afforded the title compound in 70% yield; melting point = 108 - 112°C; R^ (C) = 0.44; R^ (D) = 0.39; NMR (CDCI3) 1.47 (m, 9H, t-butyl CH3); 2.3 - 3.11 (m, 6H, asn CH2, butyl CH2-1,4); 3.2 - 5.14 (m, 8H, butyl CH-2,3, asn CH-α, CH2-1,4,
BAD ORIGINAL A
OH); 5.14 - 6.1 (m, 2H, NH); 6.6 - 7.4 (m, 10H, aromatic, NH); 7.62, 7.77,
7.87 (3 x m, 1H, 1H, 1H, aromatic,; 8.1 - 8.4 (m, 3H, aromatic,; 9.11 (m,
1H, asnNH).
EXAMPLE 19 t-Butvl 3-isopropvl-3-f(2S. 3S)-2-hvdroxy-3-(Dhenvlmethoxvcarbonyl)-amino4-phenylbutvllcarbazate
Step A: 2(R,-3(S,-1,2-Epoxy-3-phenylmethoxycarbonylamino-4-phenylbutane: To a stirred solution of 6.02 g (40 mmol) of sodium iodide in 50 ml of anhydrous acetonitrile was added 2.6 ml (22 mmol) of chlorotrimethylsilane 10 under nitrogen. After 10 minutes of stirring, 6 g (20.1 mmol, of the predominantly erythro isomer of 2{R,S)-3(S)-1,2-Epoxy -3-phenylmethoxycarbonylamino-4-phenylbutane (Example 6, Step A, was added and stirring was continued for additional 1 hour. To this mixture was added 4g (61.2 mmol) of zinc dust followed by 6 ml of acetic acid. The resulting mixture was vigorously stirred for about 5 hours at room temperature and the solid material was removed by filtration. The filtrate was evaporated to dryness in vacuo and the residue was diluted to 75 ml with ether, washed with water and 5N aqueous sodium thiosulfate and dried over anhydrous magnesium sulfate. Evaporation |n vacuo and purification by chromatography on silica gel (hexane/ethyl acetate 4:1) gave 5.1 g (90%) of (S)-2-(phenylmethoxycarbonyDamino -1-phenylbut-3-ene; R^ (A) = 0.5; melting point = 87 - 88°C (hexane); NMR (CDCI3, 2.87 (d, 2H, butene CH2-I,; 4.77 (m, 2H, butene CH2-4); 5.0 (m, 1H, NCH,; 5.06 (s, 2H, methoxy CH2); 5.18 (broad d, 1H, NH); 5.55 - 6 (m, 1H, butene CH-3); 7.19, 7.27 (m, s, 5H, 5H, aromatic).
This material (2.23 g; 7.93 mmol, was dissolved in 25 ml of dry methylene chloride and 4.5 g (22.1 mmol) of 85% 3-chioroperoxybenzoic acid was added at +4°C. The resulting mixture was stirred for two days at the above temperature, then diluted to 50 ml with ether, washed sequentially with 0°C 10% aqueous sodium sulfite solution, saturated aqueous sodium bicarbonate 30 and saturated aqueous sodium chloride and dried over magnesium sulfate. After evaporation of the solvent the crude product was purified by crystallization from a mixture of hexane/methylene chloride to give 2.1 g (89% yield) of the title epoxide with the predominant threo stereochemistry; melting point = 83 - 84°C; NMR (CDCI3, 2.47 (m, 5H, butane CH2-1.4, 35 CH-2); 3.74 (m, 0.15H, NCH,; 4.2 (m, 0.85H, NCH); 4.53 (broad d, 1H, NH);
5.03 (m, 2H, methoxy CH2,; 7.3 (m, 10H, aromatic).
BAD ORIGINAL
Step B: t-Butyl 3-iscpropyl-3-[(2S, 3S)-2-hydroxy-3-(phenylmethoxycarbonyl) amino~4-phenylbutyl]carbazate: A mixture of 2.03 g (6.83 mmol) of the product of Step A and 1.2 g (7.6 mmol) of t-butyl 3-isopropylcarbazate in 8 ml of isopropanol was stirred for 12 hours at 70 ± 5°C under nitrogen.
After evaporation of the solvent in vacuo the solid residue was recrystallised from hexane to give 2.6 g (80% yield) of the title compound melting at 114115°C; Rf (A) = 0.2; Rf (B) = 0.61; NMR (CDCI3) 0.95 (m, 6H, isopropyl CH3); 1.42 (s, 9H, t-butyl CH3); 2.44 (m, 2H, butyl CH2-1); 2.94 (m, 3H, butyl CH2-4, CH-3); 3.33 -3.93 (m, 2H, isopropyl CH, butyl CH-2); 4.4 10 (broad m, 1H, OH); 5.05 (s, 2H, methoxy CH2); 5.33 (broad m, 2H, NH); 7.18, 7.27 (m, s, 5H, 5H, aromatic).
EXAMPLE 20 t-Butyl 3-isopropyl-3-f(2S. 3S)-2-hydroxv-3-(N-quinaldovl-L-asparaqinyl)amino-4-phenylbutyl)carbazate 15 When the product of Example 19 was substituted for t-butyl 3isopropyl-((2R, 3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]carbazate in Example 3, the identical process afforded the title compound in 66% yield; melting point = 203 - 204°C (chloroform); R^ (C) = 0.36; Rf (D) = 0.37; NMR (5% CD3OD in CDCI3); 1.0 (m, 6H, isopropyl 20 CH3); 1.4 (s, 9H, t-butyl CH3); 2.53 (d, 2H, butyl CH2-1); 2.87 (m, 4H, asn
CH2, butyl CH2-4); 3.13 (s, 6H, CD30H); 3.42 (m, 2H, isopropyl CH, butyl CH-3); 4.0 (m, 1H, butyl CH-2); 4.89 (m, 1H, asn CH-a); 7.11 (m, 5H, phenyl); 7.41 - 8.47 (m, 6H, quinaldoyl).
EXAMPLE 21 cis-1.6-3-t-Butoxvcarbonyl-4-f2S. 3S)-2-hydroxy-3-(phenvlmethoxvcarbonyl)am?no-4-phenylbutvll-3,4-diaza-bicy clo Γ4.4.01 decane
When the product of Step A, Example 8, is substituted for t-butyl
3-isopropyl-carbazate in Example 19, Step B, the identical process afforded the titled compound in 78%; melting point = 110 - 111 °C (hexane); R^ (A) 30 = 0.28; Rf (B) = 0.63; NMR (CDCI3) 1.0 - 2.18 (m, 19H, decane
CH2-7,8,9,10, CH-1,6, t-butoxy CH3); 2.4 (m, 2H, decane CH2-5); 2.75 4.1 (m, 8H, decane CH2-2, butyl CH2-1,4, CH-2,3); 4.93 (broad s, 1H, OH); 5.07 (s, 2H, methoxy CH2); 5.31 (broad m, 1H, NH); 7.22, 7.32 (m, s, 5H,
5H, aromatic).
EXAMPLE 22 cis-1,6-3-t-Butoxvcarbonyl-4-f(2S, 3S)-2-hvdroxy-3-amino-4-phenylbutyl]-3.4diaza-bicvclof4.4.01decane
According to the method of Example 2, step B, the product of Example
S 6 £ 0 0 0 dV
BAD ORIGINAL &
{2 g; 0.037 mol) was converted quantitatively to the title compound (1.5 g of a heavy syrup); NMR (CDCI3) : 1.0 - 2.32 (m, 19H, decane CH27,8,9,10, CH-1,6, t-butoxy CH3); 2.32 - 4.54 (m, 13H, butyl CH2-1,4, CH2,3, decane CH2-2,5, NH2, OH); 7.28 (m, 5H, aromatic).
A fractional crystallisation of the above product from hexane gave 0.74 g of isomer A as a colorless solid melting at 123 -124°C; NMR (CDCI3) 1.0 2.25 (m, 21H, decane CH2-7,8,9,10, CH-1,6, t-butoxy CH3, NH2); 2.35 3.0 (m, 5H, butyl CH2-1,4, CH-3); 3.05 - 3.4 (m, 3H, butyl CH-2, decane CH2-5); 3.5 (m, 2H, decane CH2-2); 3.82 (d, 1H, OH); 7.27 (m, 5H, aromatic).
The hexane fraction gave 0.76 g of isomer B, after evaporation of the solvent. This was purified by column chromatography (silica gel, 8% methanol in methylene chloride; Rf = 0.16) to give 0.72 g of pure isomer B as a colorless syrup: NMR (CDCI3) 1.0 - 2.4 (m, 21H, decane CH2-7,8,9,10,
CH-1,6, t-butoxy CH3, NH2>; 2.4 - 3.1 (m, 6H, butyl CH2-1,4, CH-2,3); 3.22
- 3.4 (m, 2H, decane CH2-5); 3.52 (m, 2H, decane CH2-2); 3.76 (d, 1H,
OH); 7.27 (m, 5H, aromatic).
EXAMPLE 23 cis-1,6-3-t-Butoxycarbonyl-4-((2S, 3S)-2-hydroxy-3-(N-quinaldoyl-L20 asparaginyl)amino-4-phenylbutyl]-3,4-diaza-bicyclo[4.4.0]decane
When the product of Example 22 (mixture of isomers A and B) was substituted for cis-1,6-3-t-butoxycarbonyl-4-((2RS,3S)-2-hydroxy-3-amino-4phenylbutyl)-3,4-diaza-bicyclo[4.4.0]decane in Example 10, the identical process afforded the title compound in 72% yield; melting point = 108 25 110°C, Rf (C) = 0.44; Rf (D) = 0.46; NMR (CDCI3, 0.71 - 2.18 (m, 19H, decane CH2-7,8,9,10, CH-1,6, t-butoxy CH3); 2.18 - 4.48 (m, 12H, asn CH2, decane CH2-2,5, butyl CH2-1,4, CH-2,3); 4.95 (m, 2H, asn CH, OH); 5.55, 6.13 (broad m,m, 2H, NH); 6.84 - 7.4 (m, 6H, aromatic, NH); 7.4 8.39 (m, 6H, aromatic); 9.22 (m, 1H, NH).
A sample of this product was separated to two isomers by reverse phase (Whatman Cg semipreparative column) high pressure liquid chromatography, using 37% of 0.1% aqueous solution of trifluoroacetic acid in acetonitrile containing 0.07% of trifluoroacetic acid and 10% of water, for the elution: Isomer A,Rf = 16.8 min.; Isomer B,Rf = 18.3 min.
When the isomers A and B of the product of Example 22 were used instead of mixture, the respective isomers of the title compound were obtained.
Isomer A: 69% yield; melting point = 110-116°C; NMR (CDCI3): 1.0
AP 0 0 0 3 9 5 bad original
- 1.8 (m, 19H. t-butyl CH3, decane CH2-7,8,9,1C, CH-1,6); 2.2 - 2.6 (m. 2H, butyl CH2-1); 2.7 - 3.3 (m, 7H, asn CH2, butyl CH2-4, CH-3, decane CH25); 3.56 (m, 2H, decane CH2-2); 4.07 |m, 1H, butyl CH-2); 5.0 (m, 1H, asn
CH); 5.4 - 5.75 (m, 2H, NH, OH); 6.1 (m, 1H, NH); 7.14 (m, 6H, aromatic,
NH); 7.63, 7.8, 8.22 (m, m, m, 1H, 2H, 3H, aromatic); 9.21 (m, 1H, asn NH).
Isomer B: 78% yield; melting pont = 122 - 126°C; NMR (CDCI3): 1.1 -1.71 (m, 19H, t-butyl CH3, decane CH2-7,8,9,10, CH-1,6); 2.2 - 2.6 (m, 2H, butyl CH2-1); 2.7 - 3.15 (m, 6H, asn CH2, butyl CH2-4 decane CH2 -5);
3.43 (m, 3H, butyl CH-3, decane CH2-2); 4.1 (m, 1H, butyl CH-2); 4.94 (m,
1H, OH); 5.0 (m, 1H, asn CH); 5.55, 6.2 (m, m, 1H, 1H, NH2); 7.14 (m,
6H, aromatic, NH); 7.63, 7.8, 8.22 (m, m, m, 1H, 2H, 3H, aromatic); 9.27 (m, 1H, asn NH).
EXAMPLE 24
1 -Trimethvlacetyl-2-f(2S,3S)-2-hydroxv-3-(phenylmethoxvcarbonvl)amino-4phenvlbutyH-2-isopropylhydrazine
Step A: 1-trimethylacetyl-2-isopropylhydrazine: A mixture of 10 g (0.086 mol) of methyl trimethylacetate and 3.2 g (0.1 mol) of anhydrous hydrazine was refluxed for 12 hr. then evaporated to dryness under reduced pressure. The residue was purified by crystallization from an ether/hexane mixture to give 9g (90% yield) of trimethylacetylhydrazide, melting at 190 191 °C. When this product is substituted for t-butyl carbazate in Step A of Example 1 the identical process afforded the title compound in 67% yield, as colorless crystals; NMR (CDCI3) 1.03 (d, 6H, isopropyl CH3); 1.18 (s, 9H, trimethyl CH3); 3.07 (m, 1H, isopropyl CH); 4,62 (broad s, 1H, NH); 7.4 (broad s, 1H, NH amide).
Step B: 1 -trimethylacetyI-2-[(2S,3S)-2-hydroxy-3-{phenylmethoxycarbonyl)amino-4-phenylbutyl]-2-isopropyl-hydrazine: When the product of Step A was substituted for t-butyl 3-isopropylcarbazate in Step B of Example
19, the identical process afforded the title compound in 69% yield; melting point = 132 - 134°C: Rf (A) = 0.07; Rf (B) = 0.33; NMR (CDCI3) 0.72 1.3 (m, 1 5H, isopropyl CH3, t-butyl CH3); 2.1 - 3.16 (m, 5H, butyl CH21,4, CH-3); 3.16 - 4.0 (m, 2H, butyl CH-2, isopropyl CH); 4.86 (s, 1H, OH); 5.08 (s, 2H, methoxy CH2); 5.4 (d, 1H, NH); 6.1 (s, 1H, NH); 7.2, 7.31 (m, s, 5H, 5H aromatic).
AP 0 0 0 3 9 5
BAD ORIGINAL ft
EXAMPLE 25
1-Trimethvlacetvl-2-f(2S,3S)-2-hvdroxy-3-(N-ouinaldoyl-L-asDarag?nvl)amino4-phenvlbutyl]-2-isopropylhvdrazine
When the product of Example 24 was substituted for t-butyl-3-isopropyI5 l(2R,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]carbazate in Example 3, the identical process afforded the title compound in 65% yield; melting point = 222 - 223.5°C; Rf (C, = 0.1; Rf (D, = 0.49; NMR (10% CD3OD in CDCI3): 0.7 - 1.31 (m, 15H, trimethyl CH3, isopropyl CH3); 2.0 3.6 (m, 9H, asn CH2, butyl CH2-1,4, CH-2,3, isopropyl CH,; 4.05 (s,
CD3OH), 5.0 (m, H, asn CH); 6.64 - 8.5 (m, 11H, aromatic,.
EXAMPLE 26
-(t-Butvlamino)carbonyl-2-((2S,3S,-2-hvdroxv-3-(N-quinaldovl-Lasparaqinvl)amino-4-phenvlbutyll-2-isopropylhvdrazine
To a vigorously stirred mixture of 0.33 g (0.0103 mol, of anhydrous hydrazine in 50 ml of dry ether was added 1 g (0.01 mol) of t-butyl isocyanate. The resulting mixture was stirred for 2 hr. at room temperature then was kept overnight at 4°C. The crystals formed were filtered off, washed with a small portion of ether and dried to give 0.94 g (72% yield, of (t-butylamino)carbonylhydrazine melting at 192-193°C. When this was substituted for t-butyl carbazate in Step A of Example 1, the identical process afforded 1-(t-butylamino)carbonyl-2-isopropylhydrazine in 58% yield as a white solid; NMR (CDCI3): 1.03 (d, 6H, isopropyl CH3,; 1.33 (s, 9H, t-butyl CH3); 3.9 (broad s. 1H, NH); 6.02 (broad s, 2H, NH amide,. When this was substituted for t-butyl 3-isopropylcarbazate in Step B of Example 19 the identical process afforded 1-(t-butylamino)carbonyl-2-((2S,3S,-2-hydroxy-3(phenylmethoxycarbonyl)amino-4-phenylbutyl]-2-isopropylhydrazine in 68% yield, as a white solid; NMR (CDCI3,: 1.0 (m, 6H, isopropyl CH3,; 1.3 (s, 9H, t-butyl CH3,; 2.33-4.22 (m, 8H, butyl CH2-1,4, CH-2,3, OH, isopropyl CH); 5.05 (s, 2H, methoxy CH2); 5.3 (m, 2H, NH); 5.91{m 1H, NH,; 7.2, 7.35 (m, s, 5H, 5H, aromatic,. When this was substituted for t-butyl 3-isopropyl[(2R, 3S,-2-hydroxy-3-(phenylmethoxycarbonyl,amino-4phenylbutyl]carbazate in Example 3, the identical process afforded the title compound in 67% yield; melting point = 119 - 125°C; Rf (C, = 0.06; Rf (D, = 0.43; NMR{CDCI3): 1.0 (m, 6H, isopropyl CH3); 1.32 (s, 9H, t-butyl
CH3); 2.24 - 3.38 (m, 7H, butyl CH2-1,4, CH-3, asn CH2,; 3.38 - 4.63 (m,
3H, butyl CH-2, OH, isopropyl CH); 5.09 (m, 1H, asn CH); 5.63 - 8.4 (m,
16H, aromatic, NH); 9.0 (d, 1H, asn NH,.
bad original s
EXAMPLE 27 t-Butvl 3-isopropyl-3-f (2S, 3S)-2-hvdroxv-3-(N-picolinovl-L-asparaqinvl)amino4-phenylbutvn carbazate
STEP A: N-picolinoyl-L-asparagine: When picolinic acid was substituted for quinaldic acid in Step A of Example 3, the identical process afforded the title compound melting at 171 - 172°C, in 68% yield, NMR(DMSO-dg) 2.75 (m, 2H, asn CH2); 4.8 (m, 1H, asn CH); 6.7 - 8.8 (m, 6H, aromatic, NH2); 9.0 (d, 1H, NH); 12.7 (broad s, 1H, OH).
STEP B: t-Butyl 3-isopropyl-3-(2S,3S,-2-hydroxy-3-(N-picolinoyl-L10 asparaginyl)amino-4-phenylbutyl]carbazate; When the product of Step A was substituted for N-quinaldoyl-L-aspargine in Example 20, the identical process afforded the title compound in 58% yield; melting point = 101 - 108°C;
Rf(C, = 0.16; Rf (D) = 0.48; NMR (CDCI3): 1.0 (m, 6H, isopropyl CH3); 1.4 (s, 9H, t-butyl CH3); 2.15 - 3.23(m 7H, butyl CH2-1,4, CH-3, asn CH2; 3.23
- 4.53 (m, 3H, butyl CH-2, isopropyl CH, OH); 4.94 (m, 1H, asn CH); 5.1 6.41 (m, 3H, NH); 6.7 - 8.7 (m, 10H, aromatic, NH); 9.05 (m, 1H, asn NH).
EXAMPLE 28 t-Butvl 3-isopropvl-3-f(2S.3S)-2-hvdroxv-3-(N-(2-pyridyl)methoxycarbonylanthraniloyl)amino-4-phenylbutvl1 carbazate
When the product of Step A of Example 4 was substituted for Nquinaldoyl-L-asparagine in Example 20, the identical process afforded the title compound in 61 % yield; melting point = 155 - 157°C; Rf (C, = 0.79; Rf (D) = 0.78; NMR (CDCI3): 1.0 (m, 6H, isopropyl CH3); 1.42 (s, 9H, t-butyl CH3); 2.33 - 3.22 (m, 5H, butyl CH2-1,4 CH-2); 3.62 (m, 1H, butyl CH-3);
4.25 (m, 1 H, isopropyl CH); 4.67 (broad s, 1H, OH); 5.3 (s, 2H, methoxy
CH2); 6.52 - 8.44 (m, 15H, aromatic, NH); 8.55 (m, 1H, NH).
EXAMPLE 29 t-Butvl 3-benzyl-3-[(2S,3S)-2-hvdroxv-3-(phenvlmethoxycarbonvl)amino-4phenylbutyll carbazate
STEP A: t-Butyl 3-benzylcarbazate: When benzaldehyde was substituted for acetone in Step A of Example 1, the identical process afforded the title compound in 69% yield as a heavy colorless syrup; NMR (CDCI3): 1.44 (s,
9H, t-butyl CH3); 3.63 (broad s, 1H, NH); 4.0 (s, 2H, CH2); 6.08 (s, 1H,
NH); 7.3 (s, 5H, aromatic,.
Step B: t-Butyl 3-benzyl-3-[(2S,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]carbazate: When the product of Step A was substituted for t-butyl 3-isopropyl carbazate in Step B of Example 19, the identical process afforded the title compound in 72% yield; melting point =
S 6 £ 0 0 0 dV
BAD ORIGINAL ft
142 - 142°C; Rf (A) = 0.16; Rf (B) = C.59, NMR (CDCI3) 1.31 (s, 9H, tbutyl CH3); 2.12 - 3.12 (m, 5H, butyl CH2-1,4, CH-3); 3.35 - 4.11 (m, 3H, benzyl CH2, butyl CH-2); 4.41 (broad s, 1H, OH); 5.05 (s, 2H, methoxy CH2); 5.2 (m, 2H, NH); 7.22 (m, 15H, aromatic).
EXAMPLE 30 t-Butvl 3-benzvl-3-f(2S,3S)-2-hydroxy-3-(N-quinaldovl-L-asparaqinvl)amino-4phenylbutylcarbazate
When the product of Example 29 was substituted for t-butyl 3-ispropyl-{(2S, 3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]carbazate in
Example 20, the identical process afforded the title compound in 71 % yield; melting point = 150-153°C; Rf (C) = 0.38; Rf (D) = 0.53; NMR (CDCI3):
1.3 (s, 9H, t-butyl CH3); 2.13 - 3.2 (m, 7H, butyl CH2-1,4, CH-3, asn CH2);
3.2-4.73 (m, 4H, benzyl CH2, butyl CH-2, OH); 5.0 (m, 1H, asn CH); 5.14 - 6.7 (m, 4H, NH); 6.7 - 8.35 (m, 1 6H aromatic); 9.25 (broad m, 1H, asn
NH).
EXAMPLE 31 t-Butvl 3-cvclohexyl-3-i(2S, 3S)-2-hvdroxy-3-(phenvlmethoxvcarbonvl)amino4—phenylbutvllcarbazate
Step A: t-Butyi 3-cyclohexylcarbazate: When cyclohexanone was substituted for acetone in Step 1 of Example 1, the identical process aforded the title compound in 59% yield as a colorless solid; NMR (CDCI3): 0.75 - 2.2 (m, 19H, t-butyl CH3, cyclohexyl CH2); 2.75 (m, 1H, cyclohexyl CH); 3.75 (broad s, 1H, NH); 6.27 (broad s, 1H, NH).
Step B: t-Butyl 3-cyclohexyl-3-[(2S,3S)-2-hydroxy-3-(phenylmethoxy25 carbonyl)amino-4-phenyIbutyl)carbazate: When the product of Step A was Γ subsituted for t-butyl 3-isopropyl carbazate in Step B of Example 18, the identical process afforded the title compound in 76% yield; melting point = 142 - 143°C; Rf (A) = 0.28; Rf (B) = 0.7; NMR (CDCI3): 0.73 - 2.0 (m,
19H, t-butyl CH3, cyclohexyl CH2); 2.53 (m, 3H, butyl CH2-1, CH-3); 3.0 (d, 2H, butyl CH2-4); 3.35 - 4.0 (m, 2H, butyl CH-2, cyclohexyl CH); 4.49 (broad s, 1H, OH); 5.13 (s, 2H, methoxy CH2); 5.35 (m, 2H, NH); 7.3, 7.4 (m, s, 5H, 5H, aromatic).
EXAMPLE 32 t-Butvl 3-cvclohexyl-3-f(2S.3S)-2-hydroxv-3-(N-quinaldovl-L35 asparaq?nyl)amino-4-phenylbutvl)carbazate
When the product of Example 31 was substituted for t-butyl 3-isopropyl-3({2S, 3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl)carbazate in Example 20, the identical process afforded the title compound in
AP η n 0 3 9 5
BAD ORIGINAL
75% yie'.d: melting point = 140 - 144°C; Rf <C) 0.42; R.‘ (D) - 0.50, NMR (CDCI3): 0.7 - 2.17 (m, 19H, t-butyl CH3, cyclohexyl CH2); 2.17 - 3.29 (m,
7H, butyl CH2-1.4, CH-3 asn CH2); 3.3 - 4.87 (m, 3H, butyl CH-2, cyclohexyl CH, OH): 4.95 (m, 1H, asn CH); 5.14 - 6.4 (m, 3H, NH); 6.62 5 8.3 (m, 12H, aromatic, NH); 9.15(d, 1H, asn NH).
EXAMPLE 33 t-Butyl 3-tsopropvl-3-H2S,3S)-2-hvdroxv-3-{N-(1-carbamoylmethvl)acrvlovl)amino-4-phenvlbutvncarbazate
STEP A: (1-CarbamoylmethyI,acrylic acid: To a mixture of 3g (0.027mol) of itaconic anhydride in 30 ml of tetrahydrofuran, 3 ml of 28% ammonium hydroxide was added. After 1 hr. the reaction mixture was evaporated to dryness under reduced pressure. The residue was dissolved in 1 5 ml of water, then acidified to pH 2 with concentrated hydrochloric acid and allowed to stay overnight at 4°. The precipitate formed was filtered off, washed with a small portion of cold water and dried to give 1.4 g (40% yield, of the title compound melting at 153 - 154°C; NMR (DMSO-dg): 3.11 (s, 2H, CH2); 5.67,6.13 (s, s, 1H, 1H, CH); 6.7, 7.9 (broad s, s 1H, 1H, NH); 12.15 (broad s, 1 Η, OH).
STEP B: t-Butyl 3-isopropyl-3-[(2S,3S)-2-hydroxy-3-(N-(1 -carbamoyl20 methyl)acryloyl,amino-4-phenylbutyl]carbazate: When the product of Step A was substituted for N-quinaldoyl-L-asparagine in Example 20, the identical process afforded the title compound in 61% yield; melting point = 118122°C; Rf (C) = 0.27; Rf (D) = 0.49; NMR (CDCI3): 1.0 (m, 6H, isopropyl CH3); 1.4 (s, 9H, t-butyl CH3); 2.49 (m, 2H, butyl CH2-1); 3.0 (m, 3H, butyl CH2-4, CH-3); 3.2 (s, 2H, methyl CH2); 3.6 (m, 1H, isopropyl CH);
4.07 (m, 1H, butyl CH-2); 4.6 (broad s, 1H, OH); 5.2-5.8 (m, 4H, acryl CH, NH); 6.4 - 7.0 (m, 2H, NH2); 7.2 (m, 5H, aromatic).
EXAMPLE 34 t-Butyl 3-iso propyl-3-f(2S, 3 S)-2-hydroxy-3-(N-2-( RS)-3-tert-butylthio-230 carbamovlmethylpropionyl)amino-4-phenylbutvHcarbazate
To a mixture of 0.057 g (0.127 mmol) of the product of Example 33 and 0.0172 ml (0.1 52 mmol) of tert-butyl mercaptan in 0.5 ml of anhydrous methanol, 1 drop of a freshly prepared 20% solution of sodium methoxide in methanol was added. After stirring for 12 hr. at room temperature the mixture was evaporated to dryness, then diluted to 10ml with ether and washed with water and saturated sodium chloride solution. After drying over anhydrous magnesium sulfate, the ether was evaporated under reduced pressure. The residue was purified by column chromatography (silica gel;
AP 0 0 0 3 9 5
BAD ORIGINAL ethyl acetete), to give C.032 g (47% yield; of tha title compound; melting point = 116 - 120°C; Rf (C, = 0.42; Rf (D) = 0.56; NMR (CDCI3): 0.6 1.63 (m, 24H, t-butyl CH3, isopropyl CH3>; 2.0 - 4.47 (m, 13H, butyl 0Η31,4, CH-2,3, isopropyl CH, methyl CH2, propionyl CH2, CH, OH); 4.82 - 6.78 (m, 4H, NH2, NH); 7.11 (m, 5H, aromatic)
EXAMPLE 35 t-Butyl 3-ΐ5θΡΓθρνΙ-3-Π25. 3S)-2-hvdroxy-3-(N-benzovl-L-asparaqinvl)amino-4phenvlbutvllcarbazate
Step A: N-Benzoyl-L-asparagine: To a vigorously stirred solution of 2 g (0.013 mol, of L-asparagine monohydrate and 2.02 g (0.014 mol, of potassium carbonate in 15 ml of water, 1.51 ml (0.013 mol, of benzoyl chloride was added dropwise, over a period of 15 min., at room temperature. The stirring was continued for 2 hour, then the mixture was extracted with 10 ml of ether and the aqueous phase was acidified to pH 2 with concentrated hydrochloric acid. The white precipitate was filtered off, washed with water and purified by crystallization from isopropyl alcohol to give 2.1 g (68% yield) of the title compound at 190-192°C; NMR (DMSOdg): 2.62 (m, 2H, CH2); 3.32 (broad s, 1H, OH); 4.72 (m, 1H, CH); 6.64 8.0(m. 7H, aromatic, NH2); 8.6 (d, 1H, NH).
Step B: t-Butyl 3-isopropyl-3-l(2S,3S)-2-hydroxy-3-(N-benzoyl-Lasparaginyl)-amino-4-phenylbutyl]carbazate: When the product of Step A was substituted for N-quinaldoyl-L-asparagine in Example 20, the identical process afforded the title compound in 65% yield; melting point = 182 185°C; Rf(C, = 0.22; Rf (D) = 0.51; NMR (CDC13/DMS0-dg, 1:1): 0.92 (m, 6H, isopropyl CH3); 1.38 (s, 9H, t-butyl CH3); 2.19 - 3.11 (m, 7H, butyl CH2-1, 4, CH-3, asn CH2,; 3.11 - 4.57 (m, 3H, isopropyl CH, butyl CH-2, OH); 4.83 (m, 1H, asn CH); 6.5 - 8.17 (m, 14H, aromatic NH); 8.56 (m, 1H, asnNH).
EXAMPLE 36
1-t-Butvloxycarbonvl-2-ff2S,3S)-2-hvdroxy-3-(phenylmethoxvcarbonvl)amino4-phenylbutvl1hexahydropyridazine
Step A: 1-t-butyloxycarbonylhexahydropyridazine: When 1,4dibromobutane was substituted for cis-1,2-cyclohexanedimethyliodide in Step A of Example 8, the identical process afforded 1-t-butoxycarbonyl-2-phenyl35 methoxycarbonylhexahydropyridazine in 65% yield; melting point = 7172°C; NMR (CDCI3, 1.15 - 1.9 (m, 13H, t-butyl CH3; CH2-4,5); 3.0, 4.15 (broad m, m, 2H, 2H, CH2-3,6); 5.2 (m, 2H, methoxy CH2); 7.35 (s, 5H, aromatic,. This was converted to the title compound in 93% yield by
S 6 £ 0 0 0 dV
BAD ORIGINAL ft hydrogenolysis, performed as described in Example 2. The product was isolated as a colorless syrup.
Step B: 1-t-buty!oxycarbonyl-2-[(2S,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]hexahydropyridazine:
When the product of Step A was substituted for t-butyl 3-isopropylcarbazate in Step B of Example 19 the identical process afforded the title compound in 71% yield, as a heavy colorless syrup; NMR (CDCI3) 1.0 - 1.87 (m, 13H, tbutyl CH3, pyridazine CH2-4,5); 2.0 - 4.0 (m, 11H, butyl CH2-1,4, CH-2,3, pyridazine CH2-3,6, OH); 5.05 (s, 2H, methoxy CH2); 5.47(d, 1H, NH); 7.19 (m, 10H, aromatic).
EXAMPLE 37
1-t-Butvloxvcarbonvl-2-f(2S.3S)-2-hvdroxv-3-(N-quinaldovl-L-asparaqinyl)amino-4-phenylbutvllhexahvdropyridazine
When the product of Example 36 was substituted for t-butyl 3-isopropyl15 [(2S,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyljcarbazate in Example 20, the identical process afforded the title compound in 65% yield; melting point = 104-110°C; Rf (C) = 0.3; Rf (D) = 0.62; NMR (CDCI3) 1.0 - 2.04 (m, 13H, t-butyl CH3, pyridazine CH2-4,5); 2.15 - 4.31 (m, 13H, butyl CH2-1,4, CH-2,3, asn CH2, pyridazine CH2-3,6, OH); 4.95 (m, IH, asn CH); 5.14 - 6.6 (m, 3H, NH); 6.8 - 8.4 (m, 11H, aromatic);
9.21 (d, 1H, asn NH).
EXAMPLE 38 cis-1.6-3-t-Butoxvcarbonvl-4-f(2S.3S)-2-hvdroxy-3-(N-quinaldovl-3-cyano-Lalanvl)amino-4-phenylbutvl]-3.4-diaza-bicyclo[4.4.Ol decane
Step A: N-Quinaldoyl-3-cyano-L-alanine: To a mixture of 0.198 g (0.69 mmol) of N-quinaldoyl-L-asparagine and 0.24 ml (1.38 mmol) of N, N-diisopropylethylamine in 1 ml of chloroform was added 0.146 g (0.71 mmol) of dicyclohexylcarbodiimide. The reaction mixture was stirred for 24 hr. at room terperature, then partitioned between 10ml of 5% sodium bicarbonate and 10 ml of ether. The aqueous phase was acidified to pH2 and the acid was taken up by extraction with chloroform (3x10ml). The organic phase was dried over anhydrous magnesium sulfate, filtered and evaporated to give 0.101 g of crude product. This was recrystallized from a small portion of methylene chloride to give 0.06 g of the title compound melting at 144 35 146°C; NMR (5% DMS0-d6 in CDCI3): 3.22 (d, 2H, ala CH2); 4.95 (m, 1H, ala CH); 7.2 - 8.57 (m, 7H, aromatic, OH); 9.19(d, 1H, NH).
Step B: cis-1.6-3-t-Butoxycarbonyl-4-[(2S,3S)-2-hydroxy-3-(N-quinaldoyl3-cyano-L-alanyl)amino-4-phenylbutyl]-3,4-diaza-biyclo[4.4.0]decane: When
AP 0 0 0 3 9 5
BAD ORIGINAL the product of Step A was substituted for N-quinaldoy’-L-asparag’ne in
Example 22 (isomer A) the identical process afforded the title compound with
67% yield, melting at 106-112°C; Rf (C) = 0.87; Rf (D) = 0.89; NMR {CDCI3) 0.7 - 2.84 (m, 24H, t-butyl CH3, decane CH2*7,8,9,10, CH-1,6, butyl CH2-I, CH-3, cyanoalanyl CH2); 2.85 - 4.65 (m, 8H, butyl CH2*4, CH2, decyl CH2*2,5. OH); 4.7 - 5.6 (broad m, 2H, cyanoalanyl CH, NH); 6.9 8.5 (m, 11H, aromatic); 8.9 (broad m, 1H, NH).
AP 0 0 0 3 9 5

Claims (15)

1. A compound of the general formula (I,:
N*
R·' £R3 O or pharmaceutically acceptable salts thereof, wherein:
5 R1 is a group R, wherein R is selected from the group consisting of hydrogen,
-R’H, -R’C(O)OR”, -R’C<O)NH2, -R'C(O)NHR, -R'C(O,NRR',
-R’NHC(O>R”, -R’NR'C(O,R and -R'C(O)R, where R and R' are independently optionally substituted (C-j-C-| glalkyl, (C3-C13)cycloalkyl, {C3-C1 Q)cycloalkyl(Ci-C-j Q,alkyI, (Cg-C24)aryl, (C7-C24)10 aralkyl, (C2-C-| gjalkenyl, (Cg-C2g)aralkenyl, (C2-C η gjalkynyi, (c8'C26^ara,kYny| θΓ heterocyclic, and R’ is an optionally substituted divalent radical derived from (Cq-C-] g)alkyl, (C3-C1 g)cycloalkyl, (C3-C1 glcycloalkyKCf-C] glalkyl, (Cg-C24)aryl, (C7-C24>aralkyl, (C2-C-| g)alkenyl, (Cg-C26)aralker|yl- (C2-C-| g)a!kynyl, (Cg-C2g)15 aralkynyl or heterocyclic, or R1 is
R4
-C-R5
I
R6 where R4, R8 and R8 are independently a group R as previously defined, or R4 has the meaning of R as previously defined and R5 and
20 R8 taken together are =0, =S, =NHor =NR;
and R2 is
R D
I II
-N-B-C-Y where R is as previously defined; D is 0 or S; Y is hydrogen, -R or -OR, where R is as previously defined, or is an amino acid, aza-amino
25 acid or peptide residue in which any functional group present is optionally protected; and B is optionally absent or is (C-j-Cg)alkylidene, wherein any one or more -CH2- groups may be replaced by -NR-, -NH-, -O- or -S- provided that the compound of Formula (I) does not contain a chain of three or more atoms which are
30 not carbon, and wherein any H atom may be substituted by a group R as previously defined; and optionally Ν*, N, and R taken together form a cyclic diazaalkane of the formula:
S6 £ 0 0 0 dV
BAD ORIGINAL &
^N-N / \ ^HCHR)^ where p is 1 to 3, each R is independently as defined above and r8 is R, -NH2. -NHR, -NR2, -COOH, -COOL, -CHO, -C(O)R, -CN, halo, -CF3, -OL, -SR, -S(O)R, -S(O)2R, -CONH2, -CONHR, -CONR2, -NHOH,
5 -NHOL, -NO2, =0, =S or -NHNH2, wherein each R is independently as defined above and each L is independently R or a hydroxyl protecting group which is labile in vivo;
or r2, N* and R^ together form a saturated or unsaturated cyclic, bicyclic or fused ring system as defined hereinbefore which may be io additionally substituted by -C(0)Y, where Y is as previously defined and is X- W - A’ - Q - A -, wherein:
A' and A independently are absent or (C-j-Cg)alkylidene which may be substituted with one or more substituents R as previously defined;
Q is —CR— —C-CRy- — CR-CRyi , ii z or ι OL O OL where L and each R, independently of the others, are as previously defined, and optionally Q and A together, or Q and A' together, or A’, Q and A together form part of a saturated or unsaturated cyclic, bicyclic or
20 fused ring system as defined hereinbefore;
W is absent or is N(R), O or S, wherein R is as previously defined; and X is hydrogen, or X1, where X1 is Ra- or RbC(O)- or RbS(O)z-, where z is 1 or 2 and Ra and Rb are independently (C*)-C}g)alkyl, (C3-C1 g)cycloa!kyl, {C3-C1 g)cycloalkyl(Ci -C-j g)alkyl, heterocyclic,
25 (C-|-Cig)alkylheterocyclic, heterocyclicICg-C^aryloxy, {C1-C13)alkoxy, (C^-C-jglalkoxyiC^g)alkyl, (Cg-C24)aryloxy(Ci-Cig)alkyl, (Ce-C^aryloxyiCi-CigJalkoxy, (Cg-C24,aryl, (Cg-C24)aryl(C1 -C-j gjalkyl, (Ce-C24)aryl(C-]-Cig)alkylheterocyclic, heterocyclicoxy(C-j-C-jg)alkyl, (C-|-C-| g)alkylamino, {Cg-C24)arylamino, (C7-C13)30 aralkylamino; any of which may be optionally substituted as
AP 0 0 0 3 9 5
BAD ORIGINAL hereinbefore defined or substituted with a group Re, where Re is a group of the formula:
Rf O
I II
Z-NH—CH—C— where Z has the meaning of Ra or Rb or is an acylated amino acid, 5 azaamino acid or peptide residue, and Rf is the side-chain of a natural amino acid in which any functional group present is optionally protected, or wherein the Z-NH bond shown is replaced by a modified isosteric bond, such as CH3-NRa-, RaCH2-NRa-, CH3-CHRa-,
HCH = CRa-, RaCH = CRa-, HCOCHRa-, RaCOCHRa-, HCHOHCHRa-, io RaCHOHCHRa-, HNRaCO-, HCF = CRa-, RaCF = CRa-, RaS(O)-,
RaS(O)2-, RaP(O)ORa-, RaP(O)(ORa)CH2-, RaP(O)(ORa)0-, RaP(O)(ORa)S-, wherein each Ra is independently as previously defined, or X is Re as previously defined,
15 or X is an optionally protected amino acid, azaamino acid or peptide residue; or when W is N(R), then X, N and the substituent R on N together may form a saturated or unsaturated cyclic, bicyclic or fused ring system as defined hereinbefore or N, A' and the substituent R on N together
20 form a saturated or unsaturated cyclic, bicyclic or fused ring system as defined hereinbefore;
or wherein any two R substituents, not necessarily vicinal, taken together are optionally substituted (C2-C-|g)alkylidene.
2. A compound according to claim 1 wherein:
25 R is selected from the group consisting of hydrogen, -R‘H, -R'C(O)OR, -R’C(O)NH2, -R’C(O)NHR, -R'C(O)NRR', -R*NHC(O)R, -R’NR’”C{O)R and -R’C(0)R, where R and R' are independently optionally substituted (C1 -C -j 2)alkyl, (C
3-C12)cycloalkyl, (C3-C12}cycIoalkyl(C-|-C6)aIkyl, (Cg-C-j g)aryl, (C7-C1 g)aralkyl, (C2-C·]2)alkenyl,
30 (C3-C1 g)ara!kenyl, (C2-Ci 2)aIkynyb (Cg-C-j g)aralkynyl or heterocyclic, and R' is an optionally substituted divalent radical derived from (C-j -Ci 2)alkyl, (C3-C12,cycloalkyl, {C3-C12>cycloalkyl(Ci -Cg)alkyi, (Cg-C-]g)aryl, {C7-C1 g)aralkyl, (C2-C-| 2)alkenyl, (Cg-Cq g)aralkenyl, (C2-Ci2)alkynyl, (Cg-C-jg)aralkynyl or heterocyclic;
35 A' and A independently are absent or (C-j-C4)alkyl’dene which may be substituted with one or more substituents R as defined in this claim, and Ra and Rb are independently 2)alkyl, (C3-C12)cycloalkyl,
BAD ORIGINAL fi (C3-C12)cycioafkvf(C-j -C^)alkyf, heterocyclic, (C1-C1 palkylheterocyclic, heterocyclic(Cg-C-j gjaryloxy, (C1-C12)a,koxy> (c1-c12)a’koxY(c1-c12}· alkyl, (Cg-Ci g,aryloxy(Ci-Ci 2la,kYi- (Cg-Ci6)aryloxy{C-j-Ci2)alkoxy, (Cg-C-| g)aryl, (Cg-C-| g)aryl(Ci-Ci 2)aIkyl (Cg-Ci g)aryl5 (CVCi2)alkylheterocyclic. heterocyclic-oxy(Ci-Ci 2)a,kyl· (Ci-C-j2)alkylamino, (Cg-C-jgjarylamino, (C7-C-j2)aralkylamino; any of which may be optionally substituted as hereinbefore defined or substituted with a group Re, where Re is a group of the formula:
Rf O
I II
Z-NH—CH—C— ;o where Z has the meaning of Ra or Rb as defined in this claim or is an acylated amino acid, azaamino acid or peptide residue, and Rf is the side-chain of a natural amino acid in which any functional group present is optionally protected, or wherein the Z-NH bond shown is replaced by a modified isosteric bond, such as CHg-NRa-, RaCH2-NRa-, CHg-CHRa-, HCH = CRa-, RaCH=CRa-, HCOCHRa-, RaCOCHRa-, HCHOHCHRa-, RaCHOHCHRa-, HNRaCO-, HCF = CRa-, RaCF = CRa-, RaS(O)-, RaS(O)2*, RaP(O)ORa-, RaP(O)(ORa)CH2-, RaP(O)(ORa)O-, RaP(O)(0Ra)S-, wherein
each Ra is independently as defined in this claim. A compound according to claim 1 of the formula (IA) R R R 0 I II | zNz vQ, | -N/oA x m H jr\ y ca) Wc
where X, Q, Y and each R are independently as defined in claim 1, a and b are independently 0 to 4, and c is 0 to 6, or where two R groups, not necessarily vicinal, taken together are -(CHR^9,mwhere m is 2-8 and r18 has the meaning of R.
4. A compound according to claim 1 having the structure represented by formula (IB):
R19
A N a’zQ'a''n’'y (IB) r20 where X, R, A’, Q, A and Y are as defined in claim 1 or either or both of A and A’ are absent, and R19 and R20 have the meaning of R as defined in
BAD ORIGINAL ft claim 1 or where R3®, Ν*, N and R2® together form a cyclic di??a?lkane as hereinbefore defined.
5. A compound according to claim 1 having the structure represented by formula (IC, or (ID):
R21 R22 R24
I i ι
x. Y (IC)
R OH R23 0
R2’ R22 R24 ι II ι II
R O R23 O wherein:
R is as defined in claim 1;
R21 is hydrogen, optionally substituted (C1 -C-j 2,aIkyl; optionally
10 substituted (Cg-C-j 2)aryl; or optionally substituted (C7-C1 g)aralkyl;
R22 js hydrogen, (C-|-Cgjalkyl; (Cy-C-jgjaralkyl, or wherein r21 and r22 taken together are -(CH2)n-, wherein n is 2-8;
R23 is hydrogen; optionally substituted (C-j -C-j 2,alkyl; (Cg-Ci 2,aryl;
(C7-C1 gjaralkyi; or wherein R22 ancj r23 taken together are -(CHR25)m-i 15 wherein m is 3-6 and R25 has the meaning of R10;
r24 is hydrogen; optionally substituted (C-|-C-j2)alkyl; optionally substituted (C7-C1 gjaralkyl; or optionally substituted (Cg-Cη 2)aryI;
or wherein NR2^ and NR2^ taken together may be a cyclic diazaalkane as hereinbefore defined; and
20 X and Y are as defined in claim 1.
6. A compound according to claim 1 which is:
(i, t-butyl 3-isopropyl-3-[(2R or S,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]carbazate, (ii) t-butyl 3-isopropyl-3-[(2R or S,3S)-2-hydroxy-3-(N-quinaldoyI-L25 valyl)amino-4-phenylbutyl]carbazate, (iii) t-butyl 3-isopropyl-3-[(2R or S,3S)-2-hydroxy-3-(N-quinaldoyl-Lasparaginy')amino-4-pheny Ibutyllcarbazate, (iv) t-butyl 3-isopropyl-3-[(3S)-2-oxo-3-(N-quinaldoyl-L-asparaginyl,amino-4-phenylbutyl]carbazate,
30 (v) t-butyl 3-(1-methyl-3-phenylpropen-3-yl)-3-[(2R or S,3S)-2-hydroxy3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]carbazate,
BAD ORIGINAL ''/i) t-buty! 3-(1-me:hy' 3-pben''|propy|)-3-[(2R or S,3S)-2-hydrcxy 3-(Nquinaldoyl-L-asparaginyl)amino-4-phenylbutyl]carbazate, (vii) cis-1,6-3-t-butoxycarbonyl-4-((2R or S,3S)-2-hydroxy-3-amino-4phenylbutyl)-3,4-diazabicyclol4.4.0]decane,
5 (viii) cis-1,6-3-t-butoxycarbonyl-4-I(2R or S,3S)-2-hydroxy-3-(phenylmethoxycarbcnyl)amino-4-phenylbutyl]-diazabicyclo(4.4.0Jdecane, (ix) cis-1,6-3-t-butoxycarbonyl-4-((2R or S,3S)-2-hydroxy-3-(Nquinaldoyl-L-valyl)amino-4-phenylbutyl]-3,4-diazabicyclo[4.4.0Idecane (x) cis-1,6-3-t-butoxycarbonyl-4-I(2R or S,3S,-2-hydroxy-3-(N-(210 pyridyl)methoxycarbonyl)-L-valyl)amino-4-phenylbutylJ-3,4-diazabicyclo[4.4.0]decane (xi) cis-1,6-3-t-butoxycarbonyl-4-((2R or S,3S)-2-hydroxy-3-(Nquinaldoy !-L-asparaginyl)amino-4-pheny lbutyl j-3,4-diazabicyclo(4.4. OJdecane, (xii) cis-1,6-3-t-butoxycarbonyl-4-((2R or S,3S)-2-hydroxy-3-(N15 quina!doyl-L-glutaminyl)amino-4-phenylbutyl]-3,4-diazabicyclo[4.4.0]decane, (xiii) cis-1,6-3-t-butoxycarbonyl-4-[(2R or S,3S)-2-hydroxy-3-(Nquinaldoyl-L-threonyl)amino-4-phenylbutyl]-3,4-diazabicyclo(4.4.0]decane, (xiv) 2-t-butoxycarbonyl-3-[(2R or S,3S)-2-hydroxy-3-(phenyImethoxycarbonyl)amino-4-phenylbutyl]-2,3-diazabicyclo(2.2.1 ]hept-5-ene,
20 (xv) 2-t-butoxycarbonyl-3-[(2R or S,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]-2,3-diaza-bicyclo[2.2.1 Jheptane, (xvi) 2-t-butoxycarbonyl-3-((2R or S,3S)-2-hydroxy-3-(N-{2-pyridylJmethoxy-L-vaIyl)amino-4-phenylbutyl]-2,3-diaza-bicyclo(2.2.1 Jheptane, (xvii) 2-[N-(1 S)(2-methyl-1-methoxycarbonylpropyl)carbamoyl]-3-[(2R or
25 S,3S)-2-hydroxy-3-[N-(2-pyridylJmethoxy-L-valylJamino-4-pheny!butylJ-2,3diazabicyclo[2.2.1 Jheptane, (xviii) 2-t-butoxycarbonyl-3-l(2R or S,3S,-2-hydroxy-3-(N-quinaldoyl-Lasparaginyl)amino-4-phenylbutylJ-2,3-diazabicyclo[2.2.1 Jheptane, (ixx) 1-[2-(2-pyridyl)methoxycarbonylamino-Jbenzoyl-2-((2R or S,3S)-230 hydroxy-3-(N-quinaldoyl-L-asparaginyl)amino-4-phenylbutylJ-2-isopropylhydrazine, (xx) 2-t-butoxycarbonyl-3-((2R or S,3S)-2-hydroxy-3-(N-quinaidoyl-Lasparaginyl)amino-4-phenylbutyl]-1,2,3,4-tetrahydrophthalazine, (xxi) 1-trimethylacetyl-2-((2R or S,3S,-2-hydroxy-3-(phenylmethoxy35 carbonyl)amino-4-phyenylbutyl]-2-isopropylhydrazine, (xxii) 1-trimethylacetyl-2-[{2R or S,3S)-2-hydroxy-3-(N-quinaldoyl-Lasparaginyl) amino-4-phenylbutylJ-2-isopropylhydrazine, (xxiii) 1-(t-butylamino)carbonyl-2-((2R or S,3S)-2-hydroxy-3-(N-quinaldoylAP 0 0 0 3 9 5
BAD ORIGINAL ft
L-asp3r3ginyl)amir,p-4-pher’ylbuTy!]-2-i‘;cp'9py!hydrazin2.
(xxiv) t-butyl 3-isopropyl-3-((2R or S,3S)-2-hydroxy-3-(N-picolinoyl-Lasparaginyl)amino-4-phenylbutyl]carbazate, (xxv) t-buty! 3-isopropyl-3-[(2R or S,3S)-2-hydroxy-3-(N-(2-pyridyl)5 methoxycarbonyl-anthraniloyl)amino-4-phenylbutyl]carbazate.
(xxvi) t-butyl 3-benzyl-3-[(2R or S,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]carbazate, (xxvii) t-butyl 3-benzyl-3-[(2R or S,3S)-2-hydroxy-3-(N-quinaldoy!-Lasparaginyl)amino-4-phenylbutyl]carbazate,
10 (xxviii) t-butyl 3-cyclohexyl-3-[(2R or S, 3S)-2-hydroxy-3-(phenyl-methoxycarbonyl)amino-4-phenylbutyl]carbazate, (xxix) t-butyl 3-cyclohexyl-3-[(2R or S,3S)-2-hydroxy-3-(N-quina!doyl-Lasparaginyl)amino-4-phenylbutyl]carbazate, (xxx, t-butyl 3-isopropyl-3-I(2R or S,3S}-2-hydroxy-3-(N-(1-carbamoyi15 methy l)acryloyl)amino-4-phenylbutyl]carbazate, (xxxi, t-butyl 3-isopropyl-3-[(2R or S,3S,-2-hydroxy-3-(N-(2(RS)-3-tertbutylthio-2-carbamoyl-methylpropionyl)amino-4-phenylbutylJcarbazate, (xxxii) t-butyl 3-isopropyl-3-[(2R or S,3S)-2-hydroxy-3-(N-(1-benzoyl-Lasparaginyl)amino-4-phenylbutyl]carbazate,
20 (xxxiii) 1-t-butyloxycarbonyl-2-[(2R or S,3S)-2-hydroxy-3-(phenylmethcxycarbonyl)amino-4-phenylbutyl]hexahydropyridazine, (xxxiv) 1-t-butyloxycarbonyl-2-[{2R or S,3S)-2-hydroxy-3-(N-quinaldoyl-Lasparaginyl)amino-4-phenylbutyl]hexahydropyridazine, (xxxv) cis-1,6-3-t-butoxycarbonyl-4-((2R or S, 3S)-2-hydroxy-3-(N25 quinaldoyl-3-cyano-L-alanyl)amino-4-phenylbutyl]-3(4-diazabicyclo(4,4,0]decane.
7. A process for preparing a compound according to claim 1, comprising reacting an amine of the formula
R D
I II
HN-N-B-C-Y ι
R3
30 with a substituted alkyl halide of the formula R4
R5—C—Hal ι
R6 wherein R, R3, R4, R5, R6, B, D, and Y are as defined in claim 1.
8. A process for preparing a compound according to claim 1, comprising reacting a compound of formula (II)
AP 0 0 0 3
9 5
BAD ORIGINAL r
*
R2i z0
X-N-C-C-C-R22. (II) ι ii ' '
R Η H with a compound of formula (III)
R» O
H-N-N-i-Y (III) R24 wherein R, X, R21, R22, R23, R24 and Y are as defined In claim 5.
5 9. A pharmaceutical composition for inhibiting a retroviral protease, comprising a therapeutically effective amount of a compound according to any one of claims 1 to 6 together with one or more pharmaceutically acceptable carriers.
10. A pharmaceutical composition according to claim 9, wherein the i0 retroviral protease Is an aspartyl protease.
11. A pharmaceutical composition according to claim 9, wherein the retroviral protease Is an HIV protease.
12. A pharmaceutical composition for the treatment of acquired Immune deficiency syndrome, comprising a therapeutically effective amount of a
15 compound according to any one of claims 1 to β together with one or more pharmaceutically acceptable carriers.
13. A method for inhibiting a retroviral protease 1n a mammal In need of such retroviral protease inhibition, comprising administering to said mammal an effective amount of a compound according to any one of claims 1 to 6.
20
14. A method according to claim 13, wherein the retroviral protease Is an aspartyl protease.
15. A method according to claim 13, wherein the retroviral protease Is an HIV protease.
APAP/P/1993/000504A 1992-03-11 1993-03-29 Amine derivatives of oxo- and hydroxy-substituted hydrocarbons. AP395A (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA002130754A CA2130754C (en) 1992-03-11 1993-03-11 Amine derivatives of oxo- and hydroxy-substituted hydrocarbons
PCT/AU1993/000103 WO1993018006A1 (en) 1992-03-11 1993-03-11 Amine derivatives of oxo- and hydroxy-substitued hydrocarbons
NZ249789A NZ249789A (en) 1992-03-11 1993-03-11 Hydrazine, carbazate and 1,2-diazacyclic derivatives and pharmaceutical compositions
AU37391/93A AU681342B2 (en) 1992-03-11 1993-03-11 Amine derivatives of oxo- and hydroxy-substitued hydrocarbons
EP93906370A EP0633881B1 (en) 1992-03-11 1993-03-11 Amine derivatives of oxo- and hydroxy-substitued hydrocarbons
BR9306058A BR9306058A (en) 1992-03-11 1993-03-11 Amine derivatives of oxo- and hydroxy-substituted hydrocarbons
US08/295,855 US5679688A (en) 1992-03-11 1993-03-11 Quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons
JP5515189A JPH07504654A (en) 1992-03-11 1993-03-11 Amine derivatives of oxo- and hydroxy-substituted hydrocarbons
RU94040859/04A RU2126794C1 (en) 1992-03-11 1993-03-11 Amino-derivatives of oxo- or hydroxy-substituted hydrazines, method of their synthesis and pharmaceutical compositions for inhibition of retrovirus protease
APAP/P/1993/000504A AP395A (en) 1992-03-11 1993-03-29 Amine derivatives of oxo- and hydroxy-substituted hydrocarbons.
CN93119079A CN1090612C (en) 1992-03-11 1993-09-11 Amine derivatives of oxo- and hydroxy-substituted hydrocarbons
US08/612,894 US5888992A (en) 1992-03-11 1994-09-12 Polar substituted hydrocarbons
US08/900,733 US5942504A (en) 1992-03-11 1997-07-25 Amine derivatives of oxo- and hydroxy- substituted hydrocarbons
US09/255,551 US6071895A (en) 1992-03-11 1999-02-22 Polar-substituted hydrocarbons

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPL130492 1992-03-11
PCT/AU1993/000103 WO1993018006A1 (en) 1992-03-11 1993-03-11 Amine derivatives of oxo- and hydroxy-substitued hydrocarbons
AU37391/93A AU681342B2 (en) 1992-03-11 1993-03-11 Amine derivatives of oxo- and hydroxy-substitued hydrocarbons
APAP/P/1993/000504A AP395A (en) 1992-03-11 1993-03-29 Amine derivatives of oxo- and hydroxy-substituted hydrocarbons.

Publications (2)

Publication Number Publication Date
AP9300504A0 AP9300504A0 (en) 1993-04-30
AP395A true AP395A (en) 1995-08-08

Family

ID=27145627

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1993/000504A AP395A (en) 1992-03-11 1993-03-29 Amine derivatives of oxo- and hydroxy-substituted hydrocarbons.

Country Status (1)

Country Link
AP (1) AP395A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3330857A (en) * 1963-07-01 1967-07-11 Pfizer & Co C N-carbazoylamino acid intermediates for polypeptides
AU5571190A (en) * 1989-05-23 1990-11-29 Abbott Laboratories Retroviral protease inhibiting compounds
AU6322190A (en) * 1989-09-28 1991-04-11 Hoechst Aktiengesellschaft Inhibitors of retroviral proteases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3330857A (en) * 1963-07-01 1967-07-11 Pfizer & Co C N-carbazoylamino acid intermediates for polypeptides
AU5571190A (en) * 1989-05-23 1990-11-29 Abbott Laboratories Retroviral protease inhibiting compounds
AU6322190A (en) * 1989-09-28 1991-04-11 Hoechst Aktiengesellschaft Inhibitors of retroviral proteases

Also Published As

Publication number Publication date
AP9300504A0 (en) 1993-04-30

Similar Documents

Publication Publication Date Title
US5942504A (en) Amine derivatives of oxo- and hydroxy- substituted hydrocarbons
AU2005268030B2 (en) Aromatic compounds
TW541302B (en) Inhibitors of protein isoprenyl transferases
TW201823208A (en) N-acyl amino acid compounds and methods of use
AP597A (en) Retroviral protease inhibitors.
BG62567B1 (en) Hiv-protease inhibitors
KR0174283B1 (en) Fused benzeneoxyacetic acid derivatives as pgl2 receptor agonists
KR20190104215A (en) JAK1 selective inhibitor
CA2913913A1 (en) Dihydropyridinone mgat2 inhibitors
CA3095164A1 (en) Calpain modulators and therapeutic uses thereof
BG64276B1 (en) Carboxamide derivatives of piperidine for the treatment of thrombosis disorders
JPH11269140A (en) Differentiation-inducing agent
WO2013048928A1 (en) Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US20220112160A1 (en) Small molecule direct inhibitors of keap1-nrf2 protein-protein interaction
US8993557B2 (en) Pyridinedione carboxamide inhibitors of endothelial lipase
CA3094820A1 (en) Modulators of g-protein coupled receptors
HUT69703A (en) Inhibitors of hiv protease
AU2009248231A1 (en) Novel N-(2-amino-phenyl)-acrylamides
AP395A (en) Amine derivatives of oxo- and hydroxy-substituted hydrocarbons.
US6258806B1 (en) Amine derivatives of oxo- and hydroxy- substituted hydrocarbons
AU2003200066B2 (en) Amine Derivatives of Oxo- and Hydroxy-substituted Hydrocarbons
SK10332000A3 (en) Antivirals
AU3739193A (en) Amine derivatives of oxo- and hydroxy-substitued hydrocarbons
WO2014201073A1 (en) Macrocyclic factor viia inhibitors
AU1015400A (en) Amine derivatives of oxo- and hydroxy-substituted hydrocarbons